Our Brain and Behavior Center helped pioneer endoscopic third ventriculostomy (ETV) — an advanced shunt-free surgery for children with hydrocephalus. This minimally invasive procedure reduces risks, complications and repeat visits to the OR. It shortens recovery time for patients, and within weeks, head size normalizes and patients can resume regular activity. It’s just one of many innovative approaches we offer. Learn more at neonatology.stanfordchildrens.org.

Our neonatology team has a strong tradition of providing innovative, high-quality care for newborns, from world-leading research and advanced simulated training to expert treatments and follow-up care. We care for the smallest and sickest newborns, many of whom need complex therapies, in our 40-bed Level IV NICU. One of 14 academic nurseries participating in NICHD, our success is driven by our team’s dedication to providing nurturing care, advancing scientific knowledge and training the next generation of neonatologists.
NeoPAP® infant respiratory support system

Simple design
Easy to use
Effective delivery

NeoPAP’s innovative design is literally a breeze...

• CPAP, high flow and resuscitation modes are built into one easy to use device, improving workflow efficiency and reducing costs.
• Baby-Trak® leak compensation and sophisticated alarms give you peace of mind and the ability to focus on the specialized needs of your RDS patients.
• The unique bonnet and patient-friendly interface support developmental care and may help reduce costly skin damage.

See what NeoPAP can do for your NICU...
Learn more at www.circadiance.com
or contact us at info@circadiance.com
Arie L. Alkalay, MD
Clinical Professor of Pediatrics
David Geffen School of Medicine
Pediatrician, Cedars-Sinai
Los Angeles, CA

M. A. Arif, MD
Professor of Pediatrics & Head, Neonatology
National Institutes of Child Health
Karachi, Pakistan

Muhammad Aslam, MD
Associate Professor of Pediatrics
University of California, Irvine
Neonatologist, UC Irvine Medical Center
Orange, California

Edward Austin, MD
Austie-Hernandez Family Medical Center
Compton, CA

Richard L. Auten, MD
Assistant Professor of Pediatrics
Duke University Medical Center
Durham, NC

Bruce G. Bateman, MD
Department of Obstetrics & Gynecology
University of Virginia
Charlottesville, VA

Sandy Beauman, MSN, RNIC
CN Caring Consulting
Albuquerque, NM

David D. Berry, BS
Wake Forest University School of Medicine
Winston-Salem, NC

Melissa K. Brown, BS, RRT-NPS, RCP
Faculty, Respiratory Therapy Program
Grossmont College
El Cajon, CA

D. Spencer Bradlo, MD
Associate Professor of Pediatrics
Medical Director, Pediatric Therapy
Medical College of Georgia
Augusta, GA

Curis D. Caldwell, NNP
UNM School of Medicine, Dept of Pediatrics
Albuquerque, NM

Ed Coombs, MA, RRT-NPS, ALCCS, FAARC
Marketing Director – Intensive Care
Key Application Field Manager – Respiratory Care, Drager Medical
Telford, PA

Jonathan Cronin, MD
Assistant Professor of Pediatrics
Harvard Medical School Chief
Neonatology and Newborn Medicine Unit
Department of Pediatrics
Massachusetts General Hospital for Children
Boston, MA

Michael P. Czervinski, RRT
Neonatal and Pediatric Critical Care
University of Kansas Medical Center
Kansas City, KS

Professor Adekunle H. Dawodu
Director, International Patient Care and Education
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Jainy Desthoar, MD
Associate Professor of Clinical Pediatrics
Children’s Hospital Center
Cincinnati, OH

Leonard Eisenfeld, MD
Associate Professor of Pediatrics
University of Connecticut School of Medicine
Division of Neonatology
Connecticut Children’s Medical Center
Hartford, CT

Samir Elhassani, MD
Neonatologist
Spartanburg, SC

Ivan Frantz, III, MD
Chairman of Department of Pediatrics
Chief, Division of Newborn Medicine
Tufts University School of Medicine
Boston, MA

Philippe S. Friedlich, MD
Associate Professor of Clinical Pediatrics
Children’s Hospital of Los Angeles
Los Angeles, CA

G. Paolo Garcia, MD
Neonatologist, Therapie Intensive
Neonatologie-Neonatalologie
Cuneo, Italy

George A. Gregory, MD
Professor of Pediatrics and Anesthesia
University of California
San Francisco, CA

Charles J. Gutierrez, PhD, RRT, FAARC
Neurorepiratory Clinical Specialist, LA
Halley VA Hospital and Assistant Professor
Pulmonary, Critical Care & Sleep Medicine
Morsani College of Medicine, University of South Florida
Tampa, FL

William R. Halliburton, RRT, BCP
Neonatal Respiratory Care Coordinator
Department of Respiratory Care
Hillcrest Baptist Medical Center
Waco, TX

Mary Catherine Harris, MD
Associate Professor of Pediatrics
Division of Neonatology
University of Pennsylvania School of Medicine
The Children’s Hospital of Philadelphia
Philadelphia, PA

David J. Hoffman, MD
Clinical Associate Professor of Pediatrics
Penn State College of Medicine
Staff Neonatologist
The Reading Hospital and Medical Center
West Reading, PA

Michael R. Jackson, RRT
Newborn Intensive Care Unit
Beth Israel Hospital
Boston, MA

Chang-Ryul Kim, BS, RRT
Associate Professor of Pediatrics
College of Medicine
Hanyang University Kuri Hospital
Seoul, South Korea

David M. Kissin, BS, RRT
Perinatal Pediatric Specialist
Maine Medical Center, Portland, ME

Sheldon Korones, MD
Director of Newborn Center
College of Medicine
Memphis, TN

Scott E. Leonard, MBA, BA, RRT
Director of Respiratory Therapy, EEG, Neurophysiology
George Washington University Hospital
Washington, DC

Raymond Malloy, MHA, RRT
Director of Pulmonary Care
Thomas Jefferson University Hospital
Philadelphia, PA

Paul J. Mathews, PhD, RRT, FCCM, FCCP,
FAARC
Associate Professor of Respiratory Care
University of Kansas Medical Center
Kansas City, KS

William Seddon, MD
Professor of Pediatrics
Co-Section Chief, Neonatology
Comer Children’s Hospital
The University of Chicago
Chicago, IL

Professor Adekunle H. Dawodu
Director, Department of Neonatology and Pediatrics
University of Kansas Medical Center
Kansas City, KS

David G. Olberg, MD
Center for Pediatric Research
Eastern Virginia Medical School
Children’s Hospital of The King’s Daughters
Norfolk, VA

Rahmi Ors, MD
Director, Department of Neonatology and Pediatrics
Professor of Pediatrics and Neonatologist
Mersin Medical Faculty
Neemnetin Erebakan University
Konya, Turkey

T. Michael O’Shea, MD, MPH
Chief, Neonatology Division
Wake Forest University School of Medicine
Winston-Salem, NC

Lisa Pappas, RRT-NPS
Respiratory Clinical Coordinator NICU
University of Utah Hospital
Salt Lake City, UT

G. Battista Parigi, MD
Associate Professor of Pediatric Surgery
University of Pavia, Italy

Richard Paul, MD
Chief, Maternal & Fetal Medicine
Department of Obstetrics & Gynecology
University of Southern California
Los Angeles, CA

Max Perlman, MD
Professor of Pediatrics
The Hospital for Sick Children
Toronto, Ontario, Canada

Boris Petrikovsky, MD
Director, Prenatal Diagnostic Unit Services
New York Downtown Hospital
New York, NY

Arun Pramanik, MD
Professor of Pediatrics
Department of Neonatal Fellowship
Louisiana State University
Health Sciences Center, Shreveport, LA

Benamambahali K. Rajegowda, MD
Chief of Neonatology
Lincoln Medical and Mental Health Center
Professor of Clinical Pediatrics
Well Medical College of Cornell University
New York, NY

Karavangattu Sankaran, FRCP, FAAP, FCCM
Professor of Pediatrics and Director of Neonatology and Neonatal Research
Department of Pediatrics
Royal University Hospital
University of Saskatchewan
Saskatoon, Saskatchewan, Canada

Istvan Seri, MD, PhD
Professor of Pediatrics
Head, USC Division of Neonatal Medicine
University of Southern California
Los Angeles, CA

Tushar A. Shah, MD, MPH
Division of Neonatology
Cincinnati Children’s Hospital Medical Center
Cincinnati, OH

Dave Swift, RRT
Ottawa Hospital – Civic Site
Campus Coordinator (Professional Practice) & Special Care Nursery Charge Therapist
Respiratory Therapy Team Lead
National Office of the Health Care Emergency Response Team (NOHERST)
Subject Matter Expert, Health Canada

Jack Tanner
NICU Clinical Coordinator
U Mass Memorial Hospital
Worcester, MA

Ottwell D. Timmons, MD
Carolina Medical Center
Charlotte, NC

Maya Vazirani, MD, FAAP
Board Certified Neonatology and Pediatrics
University of Illinois
Chicago, IL

Max Vento, MD
Associate Professor of Pediatrics
Chief, Pediatric Services
Neonatology Hospital Virginia del Consuelo
Valencia, Spain

Dharmapuri Vidyasagar, MD
Professor of Pediatrics
Department of Pediatrics
University of Illinois
Chicago, IL

neonatal INTENSIVE CARE
Vol. 29 No. 3
Summer 2016

Table of Contents

DEPARTMENTS
6 News

ARTICLES
15 Protecting Patients and Practitioners
18 Nutrition Guidelines for an Exclusive Human Milk Diet
19 Value of Capnography in Infants
23 Can Weekly Antepartum Testing Decrease Near Term and Term Stillbirth?
25 Redefining the Meaning of Term Pregnancy – Beware of The Risk of Stillbirth
28 A Safe Pressure Relief Gel Device
32 Neonatal Research: Great Advances Over Time, But Keep Research Moving Forward
35 System For Low-Resource Areas To Determine Probable Causes Of Stillbirth, Neonatal, And Maternal Death
44 Antimicrobial therapy in neonatal intensive care unit
49 Neonatal Effect Of Remifentanil In General Anaesthesia For Caesaean Section
Human milk makes all the difference

The American Academy of Pediatrics’ (AAP) policy recommends the use of human milk for all preterm infants, whether mother’s own milk (MOM) or pasteurized donor human milk when mother’s own milk is unavailable.

Only Prolacta Bioscience, the leader in the science of human milk, provides:

• A full line of human milk-based nutrition for premature infants
• Human milk products that undergo the most rigorous testing and screening in the industry

To provide your preterm patient with a 100% human milk-based diet, call:
1-888-PROLACT (1-888-776-5228)
www.prolacta.com

One Device Better Than Two

Masimo announced that its SET Measure-through Motion and Low Perfusion pulse oximetry has now been integrated into ACUTRONIC Medical System AG’s fabian HFO Neonatal Critical Care Ventilator for improved patient outcomes. The fabian HFO, the world's first dedicated Neonatal Ventilator to offer Masimo SET pulse oximetry, provides continuous display of newborn oxygenation status. Instead of using two separate devices to collect ventilation and oxygenation patient data, clinicians now simply attach the pulse oximetry sensor via USB interface to the fabian HFO to display oxygenation, perfusion index and pulse rate values on the ventilator’s color touchscreen. This combined technology platform is expected to optimize patient assessments and improve workflow, allowing clinicians to spend more valuable time tending to patients. Masimo said its SET pulse oximetry has been shown to virtually eliminate false alarms and increase a clinician’s ability to detect life-threatening events, helping to substantially contribute to improved patient outcomes and patient safety. The clinical accuracy of Masimo SET pulse oximetry has also been shown to help clinicians significantly reduce retinopathy of prematurity (ROP), screen for critical congenital heart disease in newborns, reduce oxygen overdose and medical errors, and save lives in post-surgical floors, recovery, labor and delivery rooms, and ICUs.

Birth Tool Found in a Dream

A tool to help babies stuck in the birth canal is earning rave reviews from the World Health Organization. Jorge Odón, an Argentine car mechanic, came up with the idea from a dream. The device will be manufactured by Becton, Dickinson and Company, or BD, of Franklin Lakes, NJ, which is better known for making syringes. The WHO will now oversee tests on 100 more women in normal labor in China, India and South Africa, and then on 170 women in obstructed labor. Information is from an article that appeared in the New York Times. Copyright The New York Times.

Saintly Donation

Marques Colston is noted for creating noise with his amazing catches across the middle of the football field, but the New Orleans Saints wide receiver is quietly helping New Orleans neonates hang on to something more important than a football—their lives. Colston donated about $100,000 to Children’s Hospital to fund the purchase of a NeoRay Digital Imaging System for the hospital’s Neonatal Intensive Care Unit. The highly portable X-ray system is specially designed for use with newborns. It may be easily moved from incubator to incubator and allows for a drastic reduction in radiation exposure; a critical need in the early days of life. Children’s Hospital is a 247-bed, not-for-profit regional medical center offering pediatric care to children from birth to 21 years. Children’s Hospital recorded 200,834 patient hospitalizations in 2014 to 2015 and 10.3 percent of births result in critical care needs. Colston has a long list of causes that he supports, including the New York Times.

Notices should be sent promptly to Circulation Department.
In term and near-term neonates with hypoxic respiratory failure (HRF)...

When do you stop the cascade?

Early intervention with INOMAX® (nitric oxide) for inhalation upon confirmation of pulmonary hypertension may help:

- Avoid higher levels of supplemental oxygen
- Improve oxygenation
- Potentially prevent the progression of HRF

Learn more at www.inomax.com

Indication

INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

Utilize additional therapies to maximize oxygen delivery with validated ventilation systems.

Important Safety Information

- INOMAX is contraindicated in the treatment of neonates known to be dependent on right-to-left shunting of blood.
- Abrupt discontinuation of INOMAX may lead to increasing pulmonary artery pressure and worsening oxygenation even in neonates with no apparent response to nitric oxide for inhalation.
- Methemoglobinemia and NO₂ levels are dose dependent. Nitric oxide donor compounds may have an additive effect with INOMAX on the risk of developing methemoglobinemia. Nitrogen dioxide may cause airway inflammation and damage to lung tissues.
- In patients with pre-existing left ventricular dysfunction, INOMAX may increase pulmonary capillary wedge pressure leading to pulmonary edema.
- Monitor for PaO₂, methemoglobin, and inspired NO₂ during INOMAX administration.
- Use only with an INOmax DS™, INOmax® DS, or INOvent™ operated by trained personnel.

Please see Brief Summary of Prescribing Information on adjacent page.

INDICATIONS AND USAGE

Treatment of Hypoxic Respiratory Failure
INOMAX® is a vasodilator, which, in conjunction with ventilatory support and other appropriate agents, is indicated for the treatment of term and near-term (>34 weeks) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, where it improves oxygenation and reduces the need for extracorporeal membrane oxygenation.

Utilize additional therapies to maximize oxygen delivery with validated ventilation systems. In patients with collapsed alveoli, additional therapies might include surfactant and high-frequency oscillatory ventilation.

The safety and effectiveness of INOMAX have been established in a population receiving other therapies for hypoxic respiratory failure, including vasodilators, intravenous fluids, bicarbonate therapy, and mechanical ventilation. Different dose regimens for nitric oxide were used in the clinical studies.

Monitor for PaO₂, methemoglobin, and inspired NO₂ during INOMAX administration.

CONTRAINDICATIONS
INOMAX is contraindicated in the treatment of neonates known to be dependent on right-to-left shunting of blood.

WARNINGS AND PRECAUTIONS

Rebound Pulmonary Hypertension Syndrome following Abrupt Discontinuation
Wean from INOMAX. Abrupt discontinuation of INOMAX may lead to worsening oxygenation and increasing pulmonary artery pressure, i.e., Rebound Pulmonary Hypertension Syndrome. Signs and symptoms of Rebound Pulmonary Hypertension Syndrome include hypoxemia, systemic hypotension, bradycardia, and decreased cardiac output. If Rebound Pulmonary Hypertension occurs, reinstate INOMAX therapy immediately.

Hypoxemia from Methemoglobinemia
Nitric oxide combines with hemoglobin to form methemoglobin, which does not transport oxygen. Methemoglobin levels increase with the dose of INOMAX; it can take 8 hours or more before steady-state methemoglobin levels are attained. Monitor methemoglobin and adjust the dose of INOMAX to optimize oxygenation.

If methemoglobin levels do not resolve with decrease in dose or discontinuation of INOMAX, additional therapy may be warranted to treat methemoglobinemia.

Airway Injury from Nitrogen Dioxide
Nitrogen dioxide (NO₂) forms in gas mixtures containing NO and O₂. Nitrogen dioxide may cause airway inflammation and damage to lung tissues. If the concentration of NO₂ in the breathing circuit exceeds 0.5 ppm, decrease the dose of INOMAX.

If there is an unexpected change in NO₂ concentration, when measured in the breathing circuit, then the delivery system should be assessed in accordance with the Nitric Oxide Delivery System O&M Manual troubleshooting section, and the NO₂ analyzer should be recalibrated. The dose of INOMAX and/or FiO₂ should be adjusted as appropriate.

Heart Failure
Patients with left ventricular dysfunction treated with INOMAX may experience pulmonary edema, increased pulmonary capillary wedge pressure, worsening of left ventricular dysfunction, systemic hypotension, bradycardia and cardiac arrest. Discontinue INOMAX while providing symptomatic care.

ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from the clinical studies does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.

Controlled studies have included 325 patients on INOMAX doses of 5 to 80 ppm and 251 patients on placebo. Total mortality in the pooled trials was 11% on placebo and 9% on INOMAX, a result adequate to exclude INOMAX mortality being more than 40% worse than placebo.

In both the NINOS and CINRGI studies, the duration of hospitalization was similar in INOMAX and placebo-treated groups.

From all controlled studies, at least 6 months of follow-up is available for 278 patients who received INOMAX and 212 patients who received placebo. Among these patients, there was no evidence of an adverse effect of treatment on the need for rehospitalization, special medical services, pulmonary disease, or neurological sequelae.

In the NINOS study, treatment groups were similar with respect to the incidence and severity of intracranial hemorrhage, Grade IV hemorrhage, periventricular leukomalacia, cerebral infarction, seizures requiring anticonvulsant therapy, pulmonary hemorrhage, or gastrointestinal hemorrhage.

In CINRGI, the only adverse reaction (>2% higher incidence on INOMAX than on placebo) was hypotension (14% vs. 11%).

Based upon post-marketing experience, accidental exposure to nitric oxide for inhalation in hospital staff has been associated with chest discomfort, dizziness, dry throat, dyspnea, and headache.

OVERDOSAGE

Overdosage with INOMAX will be manifest by elevations in methemoglobin and pulmonary toxicities associated with inspired NO₂. Elevated NO₂ may cause acute lung injury. Elevations in methemoglobin reduce the oxygen delivery capacity of the circulation. In clinical studies, NO₂ levels >3 ppm or methemoglobin levels >7% were treated by reducing the dose of, or discontinuing, INOMAX.

Methemoglobinemia that does not resolve after reduction or discontinuation of therapy can be treated with intravenous vitamin C, intravenous methylene blue, or blood transfusion, based upon the clinical situation.

DRUG INTERACTIONS

No formal drug–interaction studies have been performed, and a clinically significant interaction with other medications used in the treatment of hypoxic respiratory failure cannot be excluded based on the available data. INOMAX has been administered with dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation. Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOMAX on the risk of developing methemoglobinemia. An association between prilocaine and an increased risk of methemoglobinemia, particularly in infants, has specifically been described in a literature case report. This risk is present whether the drugs are administered as oral, parenteral, or topical formulations.

INOMAX® is a registered trademark of INO Therapeutics LLC, a Mallinckrodt Pharmaceuticals company.

© 2015 Mallinckrodt.  IMK111-01540 R1  July 2015
visits in 2012, with children coming from 64 parishes in Louisiana, 37 states and 6 foreign countries. In all, 60,557 children received care from the hospital in 2012.

Costs Vary in NY Hospitals
Just how expensive is your hospital? In New York, the answer may lie in a trove of hospital cost data newly posted online by the State Health Department. As part of an effort to make health care pricing more transparent, the state is naming hospitals and listing their median charges and costs for 1,400 conditions and procedures from 2009 to 2011. In 2011, prices ranged from the $8 bill at Benedictine Hospital in Kingston, NY, for treating a case of gastritis (cost: $2), to a $2.8 million charge for a blood disorder case at University Hospital of Brooklyn that cost it $918,462. Hospital trade groups, which opposed the release of the database, say the figures will only confuse consumers, who rarely pay the sticker price for hospital care, especially if they have insurance. The hospitals also argue that cost figures, though based on reports to the government by the hospitals themselves, cannot be reliably compared because the state did not edit them for deaths, transfers and aberrations. Among the most common hospital admissions each year are cases of childbirth and the routine medical care of healthy newborns. There, too, the database shows extreme and unpredictable variations in cost, markups and charges. AO Fox again seems like a bargain, the rare hospital that charged less, on average, for its 140 vaginal deliveries with minor severity than its reported median cost—$1,998 versus $2,603. At Westchester Medical Center in Valhalla, on the other hand, 183 deliveries coded the same way cost $6,692 and were charged at $22,413, among the most expensive such cases in the state. Maimonides Medical Center in Brooklyn spent $1,675 per case of newborn care and charged $5,400, while at Montefiore Medical Center in the Bronx, the cost was $2,586 and the price $10,950. Information is from an article that appeared in the Connect by Lindsay Gellman. Copyright Connect.

Study Goes Nuts
Pregnant women who eat more peanuts and tree nuts during pregnancy might be less likely to bear nut-allergic children, a new study suggests. Pregnant women who eat more peanuts and tree nuts during pregnancy might be less likely to bear nut-allergic children, a new study suggests. The research, published in the Journal of Allergy and Clinical Immunology, is from an article that appeared in the Connect by Lindsay Gellman. Copyright Connect.

Home Births Linked to Complications
The small but rapidly increasing number of women who choose to give birth at home may want to consider new research indicating that home births are linked to increased neonatal complications, including seizures. Researchers from Oregon Health & Science University and University of California at San Francisco, which studied babies born in 2008, found that home birth nearly doubled the risk for Apgar scores of four or lower on a 10-point scale; seven is considered normal. The scores evaluate newborns based on appearance, pulse, grimace, activity and respiration. Although educated and married white women over
age 35 were most likely to choose home birth, the researchers controlled for age, race, gestational age at birth, among other factors. The home birth mothers in the study were less likely than others to experience induced labor or an assisted delivery, and researchers found that home births attended by certified nurse-midwives yielded complication rates not much different from hospital births. Nurse-midwives presided over more than a quarter of these home births.

Reality of Resuscitation Times

A new study suggests many newborns are not being managed within resuscitation guidelines and that the recommended intervals may be too short. The study—through a team of researchers in Dublin, Ireland, including at the Department of Neonatology, National Maternity Hospital—said that most newborns in the study “were not managed within the time frame recommended in resuscitation guidelines. The recommended 30- and 60-second intervals may be too short.” Researchers were looking to determine whether resuscitation teams were able to adhere to the recommended algorithm for newborn resuscitation. Video recordings were made of delivery room resuscitations of 194 high-risk neonates (gestational age 27-34 weeks; mean, 29 weeks) at 2 hospitals. Staff in these hospitals were trained to follow the NRP algorithms in the delivery room and were experienced in neonatal resuscitation. Interventions in newborn resuscitation, known as “initial steps,” involve placing the newborn who requires assistance on a radiant warmer, then towel-drying or placing the newborn’s body in a polyethylene bag; positioning the airway (and clearing the airway if needed); assessing the infant’s respiratory effort and heart rate; and stimulating the infant to breathe, if necessary. These steps are intended to be accomplished by 30 seconds of age, and the clock starts ticking at the time of birth, not the time when the infant is placed on a radiant warmer. According to the study, called Timing of Interventions in the Delivery Room: Does Reality Compare With Neonatal Resuscitation Guidelines, “the median time taken to perform all tasks was greater than that recommended in the guidelines.”

‘Terms’ of Endearment

Concerned by trends to induce labor or schedule cesarean deliveries earlier than 39 weeks gestation for a single fetus, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine has issued four new definitions of ‘term’ deliveries to clarify matters for women and doctors. The new definitions are based on the duration of pregnancy calculated from the first day of a woman’s last menstrual period, a known date of conception, or an ultrasound measurement of the fetus during the first 13 weeks of pregnancy: early term, between 37 weeks, 0 days and 38 weeks, 6 days; full term, between 39 weeks, 0 days and 40 weeks, 6 days; late term, between 41 weeks, 0 days and 41 weeks, 6 days; post term, 42 weeks, 0 days and beyond. The college hopes this terminology change makes it clear to both patients and doctors that newborn outcomes are not uniform even after 37 weeks. The college advocates patience: observing mother and fetus weekly, and allowing nature to take its course when there is no reason to intervene. If it is important to schedule a C-section or to induce labor in an otherwise healthy pregnancy, “after 39 weeks is appropriate,” the college said.

Risk of Infections Elevated

A study suggests increased infections could be created with longer duration PICC placement. According to study author Dr Aaron M Milstone of Johns Hopkins University, peripherally inserted central catheters (PICCs) are often used in the neonatal intensive care unit (NICU) to aid in the delivery of medications and nutrients to neonates. However, PICCs can also be the culprit of central line associated blood stream infections (CLABSIs). Dr Milstone said the multicenter, retrospective cohort study looked at the temporal relationship between PICC insertion and development of CLABSI. Through this analysis, researchers found an elevated risk of CLABSI when PICC placement went beyond 7 days as opposed to shorter durations. This increase in risk persisted for 2 weeks after placement, and then remained elevated, but stable for the duration of the PICC. While Gram-positive infections were the most common etiology of CLABSIs in PICCs, an increase in Gram-negative infections was noted when PICC duration exceeded 50 days. This study’s multicenter design limited consistency in data collection and reporting across included institutions. This research suggests ongoing attention to necessity of PICCs, and to further quality improvement measures to decrease occurrence of CLABSIs. Given the noted incidence of CLABSIs with PICC dwelling time, the judicious placement and removal of PICCs could be warranted to prevent infections.

Later Not Necessarily Better

A study suggests that a shift in practice away from elective late preterm delivery to early term deliveries has shown little impact on neonatal outcomes such as intensive care length of stay, neonatal morbidity, or mortality in a population with major congenital heart disease. Researchers at Columbia University Medical Center and Morgan Stanley Children’s Hospital, both in New York, sought to evaluate the effect of a change in delivery practice that was introduced following the 2009 publication of a study showing improved outcomes in infants delivered after 39 weeks. Medical records were reviewed for infants with critical congenital heart disease and compared outcomes in 878 infants born at a single tertiary center during 2004-2008 to outcomes in 124 infants born in 2010, after the change in practice had been implemented. There was a significant increase in the mean gestational age (37.8 weeks vs. 38.4 weeks, respectively; P less than .01) and in mean birth weight (2,975 grams vs 3,134 grams; P less than .01). However there were no significant differences between 2004-2008 and 2010 data in 5-minute Apgar scores (8.5 vs. 8.6; P = .11), median length of stay (14 days [1-197] vs. 16 days [1-144]; P = .18) and neonatal mortality (6% vs. 11%; P = .07), according to data presented at the International Society of Ultrasound in Obstetrics and Gynecology world congress.

Information is from an article that appeared in the News Digital Network. Copyright News Digital Network.

Neonatal Webcam Gets Thumbs Up

Parents are praising a webcam system for letting them monitor their babies’ progress at the Anya Marie Jackson Neonatal Intensive Care Unit at Aspirus Wausau Hospital. The webcam system, called NICVIEW, includes cameras in each room of the intensive care unit that can be positioned over each baby. Families are given secure, encrypted login information that they can pass along to friends and family members who can log in any time to monitor a baby’s progress. There is no charge for the service. With this new system, parents, friends or family members can log in from a computer, a tablet or a smartphone and see the baby and what’s happening inside the NICU. The NICVIEW system cost $51,990 and funding was made possible through the 2013 Aspirus Women’s Golf Classic. Nearly 300 golfers, caddies and volunteers partnered with Aspirus and...
Because Tiny Feet Deserve a Tiny Touch

Tiny feet can offer big challenges when it comes to neonatal capillary testing. Unistik TinyTouch is designed to deliver a precise and kinder incision during neonatal blood sampling, for happier babies and healthcare workers.

FREE SAMPLE REQUEST

YES! I’m interested in trying Unistik TinyTouch Heel Incision Device for free! To receive samples and literature please fax this sheet back to 770-977-2866, call 1-800-421-6936 or email samples@owenmumfordinc.com!

NAME: 
TITLE: 
FACILITY NAME: 
ADDRESS: 
CITY: STATE: ZIP: 
PHONE: EMAIL: 

Please allow 8-10 weeks for delivery of samples. While supplies last. No purchase necessary.
nearly 100 businesses and community members to help make the purchase possible.

Exercise Could Affect Babies’ Brains
A study of expectant mothers and their newborns says physically active pregnant women increase the development of their unborn child’s brain. Researchers at the University of Montreal in Canada recruited a group of local women who were in their first trimester of pregnancy. The women were randomized either to begin an exercise program, commencing in their second trimester, or to remain sedentary. The women in the exercise group were asked to work out for at least 20 minutes, three times a week, at a moderate intensity, equivalent to about a six or so on a scale of exertion from one to 10. Most of the women walked or jogged. Every month, for the remainder of each woman’s pregnancy, she would visit the university’s exercise lab, so researchers could monitor her fitness. All of the volunteers, including those in the non-exercise group, also maintained daily activity logs. After about six months and following the dictates of nature, the women gave birth. All had healthy boys or girls— which the scientists gently requested that the mothers almost immediately bring in for testing. Within 12 days of birth, in fact, each of the newborns accompanied his or her mother to the lab. There, each baby was fitted with an adorable little cap containing electrodes that monitor electrical activity in the brain, settled in his or her mother’s lap, and soothed to sleep. Researchers then started a sound loop featuring a variety of low, soft sounds that occurred frequently, interspersed occasionally with more jarring, unfamiliar noises, while the baby’s brain activity was recorded. The study found brainwave activity soared in response to the novel sounds among the children born to mothers who had remained sedentary during pregnancy. But it was noticeably blunted in the babies whose mothers had exercised. Information is from an article that appeared in the New York Times. Copyright The New York Times.

Drinking Study Upsets Group
A Danish study on the behavioral outcomes of children whose mothers consumed alcohol during pregnancy is being called potentially harmful by Fetal Alcohol Syndrome (FAS) experts because of the media coverage it has generated. “It’s deeply concerning,” said Dr Kenneth Lyons Jones, who is president of MotherToBaby, a service of the international non-profit Organization of Teratology Information Specialists, and professor of pediatrics at the University of California, San Diego. The research causing such concern among experts over misinterpretation is a series of studies out of the University of Copenhagen. “The take-home message of this study should in no way be to encourage drinking in pregnancy as a means to better mental health for children,” Dr Jones said. Janni Niclasen, a psychologist, surveyed approximately 37,000 Danish women who reported on drinking habits during pregnancy. The study results showed that women who drank as much as one glass of wine per week had children with better emotional and behavioral outcomes by age seven compared to children of mothers who claimed to not drink at all. However, the author also points out that mothers who reported drinking tended to be more educated and have other potentially healthier characteristics overall. In addition, the author points out that the timing of the alcohol exposure during the surveyed pregnancies, which can play an important role in how the fetus is affected, was ignored. According to a statement from MotherToBaby, the study does not show that drinking caused mothers to have children with fewer behavioral concerns — rather that mothers who reported drinking were very different from mothers who did not in multiple ways. These differences in family and home environment, along with the way that alcohol exposure and child health were measured could easily mask any associations with low-level alcohol.

Helpful Bacteria Can Also Harm
Cells that allow helpful bacteria to safely colonize the intestines of newborn infants also suppress their immune systems to make them more vulnerable to infections, according to new research in Nature. The study could prompt a major shift in how medicine views the threat of neonatal infections and how researchers go about looking for new strategies to stop it, said scientists at Cincinnati Children’s Hospital Medical Center who conducted the research. Leading up to this study, the prevailing view has been that newborn infants are susceptible to infection because their immune system cells are immature or underdeveloped. The study suggests this is caused by active immune suppression during this developmental period, as opposed to the immaturity of immune cells. The suppressive cells in this case are CD71+ precursors of mature red blood cells. The researchers found CD71+ precursor cells are enriched in newborn mice (and in human umbilical cord blood) to prevent an over reactive immune response as infants adapt to their new microbe-filled world. CD71+ cells express an enzyme called arginase-2 that is essential to suppress immune cells. Researchers said this process plays a vital role in infants’ developing intestines by preventing an onslaught of inflammation in response to colonizing bacteria that help digestion and related functions. Researchers used a series of laboratory tests in human blood cells and mouse models to show temporary immune suppression in newborns extends beyond the intestines to also affect other parts of the body.

Breakthrough in Neonatal Diabetes
Researchers at University of Exeter Medical School in Britain say they have discovered two new genetic causes of neonatal diabetes, a rare disease that affects approximately 1 in 100,000 births. Neonatal diabetes is caused by a change in a gene which affects insulin production. This means that levels of blood glucose (sugar) in the body rises dangerously high. The team discovered that mutations in two specific genes which are important for development of the pancreas can cause the disease. The study focused on 147 young people with neonatal diabetes. Following a systematic screen, 110 patients received a genetic diagnosis. For the remaining 37 patients, mutations in genes important for human pancreatic development were screened. Mutations were found in 11 patients, four of which were in one of two genes not previously known to cause neonatal diabetes—NKX2-2 and MNX1. The genetic discovery is critical to the advancement of knowledge on how insulin-producing beta cells are formed in the pancreas. This could one day lead to a cure for neonatal diabetes, said the paper published in the journal Cell Metabolism.

Hospital Doesn’t Drink Decaf
Caffeine has been shown to help reduce the risk of neurological (brain) damage in premature infants, help infants come off ventilators (breathing machines) sooner, as well as help infants who have stopped breathing (apnea), according to research from the Cone Health Women’s Hospital in North Carolina. The team of pharmacists at Women’s Hospital has researched and published a report providing the range of caffeine levels that are appropriate for each condition. It found different levels and forms of caffeine must be administered for each situation. This
research provides the neonatal care team with a base line to help individualize the caffeine dosage each infant needs to receive the optimal benefits. This is just one research study done in collaboration with the Neonatal Pharmacotherapy Education Program. The goal is to advance the neonatal care that premature infants and full-term infants who have experienced certain complications at birth receive at Women's Hospital. At Women's Hospital, the dosing of antibiotics is individualized from the first dose because several studies performed by the neonatal pharmacists and physicians at Women's Hospital showed that the dosing guidelines from dosing handbooks were not reliable at achieving blood levels needed for effective treatment, while also avoiding damage to the kidneys and ears. Instead, blood levels of the antibiotic are drawn twice after the first dose, and the pharmacists use special calculations to make sure the most effective and safe levels are achieved to help infants get better and home to their families as quickly as possible.

**Distance From Hospital a Risk**

Infants with hypoplastic left heart syndrome (HLHS) born far from a hospital providing neonatal cardiac surgery for the condition have increased neonatal mortality, with most deaths occurring before surgery, according to a new study. Researchers led by Texas Children's Hospital and Baylor College of Medicine (BCM), published online in the journal, Circulation, also concluded that efforts to improve prenatal diagnosis of HLHS and subsequent delivery near a large volume cardiac surgical center may significantly improve neonatal HLHS survival. HLHS occurs when the fetus's left side of the heart does not develop normally, and is present in approximately 1 in 6,000 live births. Of the more than 3.4 million births during the study period, 463 infants with HLHS were assessed. Mothers delivering farther from a cardiac surgical center were less educated and more often lived in a poverty-stricken area. Additionally, 39 percent of newborns studied were prenatally diagnosed with HLHS and delivered significantly closer to a cardiac surgical center. Forty percent of newborns with HLHS died that were born more than 90 minutes from a cardiac surgical center, compared to 21 percent of those born within 10 minutes of a surgical center. The percentage of patients that died after the first surgery for HLHS was two to four times higher in low volume surgical centers than in the highest volume centers. Overall, in the latest years of the study, newborns with a prenatal diagnosis, born less than 10 minutes from a cardiac surgical center, and cared for at a large volume cardiac surgical center, had a neonatal mortality of 6 percent. For those born in the same era without a prenatal diagnosis, more than 10 miles from a cardiac surgical center, and cared for at a low volume cardiac surgical center, 28-day mortality was 29 percent.

**Plan Set for Infant Mortality**

The health department of India has developed a plan to reduce infant mortality in the country by implementing certain clinical guidelines and quality standards that are expected to change the manner in which neonatal care is practised in major hospitals. The department teamed with Access International, a not-for-profit organization that works with governments and provides research and training inputs to improve health care service delivery and processes. Four working groups, including pediatricians, neonatologists, obstetricians, and infection-control specialists, conducted several research studies to provide guidance on the care infants receive in neonatal ICUs.

Neonatal Whole Body Cooling is shown to improve outcomes for newborns meeting the requirements for HIE. Cincinnati Sub-Zero's Blanketrol® III with it’s “Gradient Technology” and the Kool-Kit® Neonate provide accurate and safe patient temperature management. This system offers the ability to reach and maintain goal temperature as well as provides controlled re-warming for the patient.

- All Therapeutic Hypothermia disposables located in one convenient package
- Self sealing/insulated blanket hoses
- Mittens/Socks allow more family contact without compromising patient temperature
- All products tested and validated by CSZ for CSZ equipment

Phone: 513-772-8810
Toll Free: 800-989-7373
Fax: 513-772-9119
www.cszmedical.com

experts from major tertiary care hospitals in the country, have been working on the basic premise—based on a study by the Indian Academy of Pediatrics (IAP)—that the major causes of infant deaths in the area of Kerala were prematurity (34.6 percent), congenital anomalies (28 percent), sepsis (9.3 percent), and birth asphyxia (8 percent). The IAP study had reported that 75 percent of the infant deaths occurred during the neonatal period, and that of the total neonatal deaths, 59 percent of the deaths occurred during the first week of life. The groups have now formulated 13 quality statements relating to antenatal, intra-partum and neonatal interventions, the practice of which is expected to make a significant dent in neonatal mortality. The majority of deliveries in the area continue to take place in the private sector, and any quality improvement program aimed at bringing down the IMR would have to include the private sector, the IAP has pointed out.

**Hospital Adds Cooling in Transport**

Texas Children’s Hospital is now the only pediatric hospital in Texas to offer active and regulated whole body cooling for infants who are oxygen-deprived at birth during ambulance transport to the hospital’s level IV neonatal intensive care unit (NICU). Previously, oxygen-deprived infants would be passively cooled prior to and during transport, where all heat sources were turned off, meaning many infants would be under-cooled or overcooled. Whole body cooling treatments are administered within six hours of birth, last for 72 hours and bring a baby’s temperature down to 33.5 degrees Celsius (92.3 Fahrenheit) to allow brain cells that would have otherwise died or been severely damaged, to survive. Texas Children’s Newborn Center, together with the hospital’s new Pavilion for Women, houses the nation’s largest NICU and is one of only two hospitals in the greater Houston area to offer whole body cooling treatments and the only pediatric hospital in Texas to offer safe and regulated active whole body cooling during ambulance transport using specialized cooling equipment.

**Computer Heeds Babies Cry**

Researchers at Brown University and Women and Infants Hospital in Providence have devised a computer program to help analyze a baby’s cries. They hope to soon make it available to researchers world-wide looking to analyze crying patterns that can’t always be detected by the human ear. The computer program breaks down cries into 12.5-millisecond frames and measures the pitch and volume, among other parameters. In total, it can evaluate 80 different parameters, which could help detect risk for conditions affecting a newborn baby’s health. Because a cry is controlled by cranial nerves, it can be a window into the brain. While researchers haven’t reached the stage where they can link cry characteristics with specific conditions, they’ve found that, on a group level, an infant’s nervous system and therefore cry can be affected by prenatal exposure to alcohol, birth injuries, and even related to later diagnoses of autism. Researchers aren’t at the stage where cries can pinpoint specific illness, although that is the ultimate goal. Today, a baby’s cry can be tapped for information on pain and the nervous system. Information is from an article that appeared in the Wall Street Journal. Copyright the Wall Street Journal.
Wrong Route Error in the NICU: Protecting Patients and Practitioners

Kim Flanagan, MSN, CRNP

Introduction
Most nurses do not envision their career ending in a horrific incident involving the harm or death of one of their patients. In fact, most of us live in fear over whether that day could ever come asking “What if that happened to me?”

It is the challenging work of the clinician to provide excellent care for their patients while minimizing risk and potential harm, particularly during hospitalization. While the patient and their families are the obvious victims in these situations, there is also another victim: the clinician. In high acuity settings, such as the NICU, these errors pose an even greater threat to the vulnerable neonatal patient and caregiver. Though many excellent strategies have been implemented to mitigate the risk of these errors, they still occur in alarming numbers. This article will review these strategies and look at the next layer of interventions to protect our patients, families and care providers from the devastating consequences of wrong route errors.

Medication errors
Medical errors occur in the United States every day, according to the Institute of Medicine’s 1999 report “To ERR is Human,” it is estimated that anywhere from 44,000 to 98,000 people die in hospitals every year as a result of preventable medical mistakes costing 17 to 29 billion dollars annually.1 Many of these errors are from medication errors: according the FDA over 30,000 medication errors have been reported since 1992 but, since these reports are not mandated, the actual estimate is thought to be much higher.2

Nursing practice includes medication management as governed by the 7 “Rights”: right medicine, right dose, right time, right patient and right route, right reason and right documentation.3 A medication error usually occurs when there is a breach in one of these rights.4 A wrong route error, also known as medical misconnection, is when a “seemingly apparent incompatible system that, when inadvertently connected, can result in life threatening events in the clinical arena.”5 An example of a wrong route error is when a nurse unintentionally places an enteral feed into an IV catheter. While not as prevalent in the literature, tubing misconnections are suspected of being underreported and when they do occur, they tend to impose grave consequences. As of 2009, “nine cases of tubing misconnections have been reported to the Joint Commission Sentinel Event Database. These events resulted in 8 deaths and 1 permanent loss of function,” including two infants.6

Second Victim Syndrome
Most errors occur from intelligent well-meaning clinicians involved in “complex clinical conditions, poorly designed processes and inadequate communication patterns.”7 Clearly the victim in these situations is the patient and their families. However, due to the severe emotional, personal and professional anguish suffered by the healthcare provider it is evident that the “second victim” is the clinician. Dr Albert Wu first identified second victim syndrome in 2000.8 According to one literature review, the prevalence of second victim syndrome varied in prevalence from 10.4 to up to 43.3%.9 Over the past 15 years, support for the healthcare professional dealing with the consequences of these situations has improved greatly. Hospitals are no longer hiding from these mistakes, but instead encouraging reporting and education thanks to government and regulatory agencies like the A.S.P.E.N, the FDA and ISMP.10 Some institutions now have support systems in place to help caregivers get help to heal from the shame and suffering of having to live with the harm they have unintentionally caused. Patients and clinicians benefit from the honest, open discussion and root cause analysis done to prevent mistakes from being repeated.

Much time and effort has also been put into mitigating the risk of these types of errors from a variety of regulatory agencies such as Joint Commission, Vermont Oxford Network, Institute for Safe Medication Practices, and the World Health Organization.11 Interventions such as tracking, bar coding, line reconciliation, computerized physician order entry, labeling changes and patient and provider education have made great strides in improving the situation. Despite these efforts, according to the WHO: “misconnections errors still occur with significant frequency with deadly consequences.” More can be done to protect both our patients and our nurses, particularly in the Neonatal Intensive Care Unit.

Risk in the NICU
According to the NANN position statement on Medication Safety, medication administration is at increased risk for
adversity related to three factors: “vulnerable nature of NICU patients, the complexity of the medications used, and the challenges of the NICU environment.”12 Examples of this include small size, non-verbal status, weight and physical immaturity.13,14 Not only are these patients at greater risk for experiencing a medication error but, because of their fragile condition, they are more likely to have a worse outcome as a result.15 The high acuity setting with its low lighting and array of tubing leaves a fatigued and over worked nurse at greater risk for harming a patient. An example of the risk associated with the NICU population is the Luer-lock or Luer-slip fit syringes which are able to fit into both IV connectors and enteral tubing. In addition feeding and medications are often infused on similar (if not the same) syringe pumps. Similar to the adult world, efforts have been made to allay these risks. Yet the incidence of medication errors are reported to be as high as 57% and occur eight times as often than in the adult population.16 Clearly, additional interventions are needed to improve patient safety.

**Design change as protection for Infant and Nurse**

One of the earliest medical misconnections documented in the literature was from 1972 when milk was inadvertently administered thru an IV.17 In 1996 the Joint Commission created a Sentinel Event Policy to assist healthcare facilities in taking steps to improve safety.18 That same year, the Association for the Advancement of Medical Instrumentation (AAMI) implemented a standard to make enteral connectors incompatible with IV Luer-lock connectors. However, because it was a voluntary step, manufacturers never developed the alternative designs and once they did they were not mandated thus were never universally adopted.19 Ten years later in 2006, Sentinel Event Issue 36 was released. In it, the Joint Commission acknowledged the risks which could lead to patient safety issues, such as look-alike multi-purpose tubing, which continued to be a problem despite best efforts.20 The Joint Commission has urged manufactures to implement design change for products that make them unique to their function. An example of this would be enteral feeding tubes and syringes that can no longer be used for anything other than enteral feeding by nature of their design. This is called force function. Enteral feeding equipment will be the first of many product design changes that will finally be brought into the market. More importantly, the same design will be shared by multiple manufactures with the goal of national standardization. As a result, hospitals will receive many benefits such as not having to change tubes when patients are transported and form institution to institution. Future areas planned for change include: connectors for flow of gases, limb cuffs, urological access, neuraxial access.21

But as we know from history, voluntary adoption of these products may lead to limited use. Finally, one state has no longer made this a voluntary option. In July 2016 the adoption of the force function design for enteral feeding, called ENFit, will become a legal requirement for all hospitals in the state of California. Thus putting into effect what A.S.P.E.N and the Joint Commission has long recommended: the physical inability for a nurse to connect enteral feeding into intravenous line (or any connection other than enteral) regardless of how busy she is or how complex the clinical environment. The effort to create a product design that allows a physical impediment to prevent a medical misconnection has been in the works for over 10 years. Researchers agree that human factors are the most frequent cause contributing to medical errors.22 Having products and equipment that have force function inherent in their design only brings us closer to our common goal: a culture of safety.

**Conclusion**

Medical mistakes happen with frightening frequency in the United States. In the NICU our patients and clinicians are at even higher risk of an adverse event. Many of our medical institutions, government and regulatory agencies have worked very hard and continue to discuss and implement strategies to decrease the risk factor that contribute to these devastating outcomes. Patient safety is a complex, multidisciplinary effort with no “one fix” solution. We have come a long way in making improvements in the area of medication safety. But we are now at the next stage when manufacturers are contributing solutions to decrease these horrific events. As hard and costly as change can be, we as care providers and administrators are now ethically obligated to utilize this next layer of protection from misconnection errors, not only for our patients, but also for the people on the front lines of patient care who treat them every day.

**References**


2 http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143553.htm


8 Wu AW. Medical error: the second victim. The doctor who makes the mistake needs help too. BMJ. 2000;320:726-727


http://www.jointcommission.org/Sentinel_Event_Policy_and_Procedures


http://www.jointcommission.org/SentinelEvents/SentinelEventAlert/sea_36.htm

https://www.ismp.org/newsletters/acute-care/articles/20100715.asp

The Nutrition Advisory Committee (NAC) comprises five neonatal dietitians from around the U.S. who have experience using an “Exclusive Human Milk Diet” (EHMD). The NAC, which is sponsored by Prolacta Bioscience, was created to provide clinical expertise, research, insights, and guidance on premature infant nutrition. They also serve as a resource to fellow clinicians for education and support around the growing use of an EHMD for extremely premature infants with a commitment to sharing ideas and evidence-based practices.

An EHMD is a diet composed of all human milk; the base of the feed is mom’s own milk, banked human milk or both. The fortification is a human milk based human milk fortifier, and, if needed, a modular made of human milk. There is a strong body of research linking an EHMD with a decrease in necrotizing enterocolitis. Through the practice of using an EHMD, we are now realizing even more potential benefits from such a diet.

The “Nutritional Advisory Committee NICU Enteral Guidelines for the use of an Exclusive Human Milk Diet for Babies ≤1250 g” was one of the first ways the committee wanted to share best practices with other clinicians. The goal was to create a resource that anyone could benefit from, whether they had experience using an exclusive human milk diet or just beginning the process of implementing one. This guideline has a foundation of well-known references in combination with the unique input from the NAC members — a compilation of best-practices from six dietitians in six NICUs. The end result is a guideline with tangible information to help in the daily nutritional management of premature infants in the NICU.

Andi Markell is a neonatal dietitian who has worked in a level 4 NICU in Portland Oregon for the last 15 years. As the first dietitian in her NICU, much of her time has been committed to developing policies and protocols. She has used an exclusive human milk diet since 2008 and has published much of her time has been committed to developing policies and protocols. She is a founding member of the Nutrition Advisory Committee from Prolacta Bioscience. This guideline is intended to provide a guideline for healthcare providers in the use of an Exclusive Human Milk Diet in infants ≤1250 g birth weight. The information within is the collective opinion of the Nutrition Advisory Committee, a committee sponsored by Prolacta Bioscience. As with all feeding guidelines, appropriate medical judgement should be exercised. Be sure to review your clinical experience and outcomes around the management of nutrition in very low-birth-weight infants.
Capnography can be a cost-effective way to monitor real-time carbon dioxide (CO₂) levels and trends in intubated and non-intubated infants and neonates. Recent innovations in capnography sampling and measurement are directed at ease of use and accuracy. Capnography provides the continuous measurement of partial pressure of carbon dioxide in the breath during inhalation and exhalation and displays:

- The partial pressure of end-tidal carbon dioxide (etCO₂ or PetCO₂), the maximal concentration of CO₂ during exhalation
- Fraction of inspired CO₂ (FiCO₂) which should generally be zero as inhaled air contains minute amounts of CO₂
- Capnogram (aka, capnograph, etCO₂ waveform) which is a graphic representation of the CO₂ waveform
- Respiratory rate derived from the waveform
- Trends of these readings

Capnography is the standard of care for continuously monitoring adequacy of ventilation for intubated patients during general anesthesia in the operating room, and is recommended by the American Heart Association and American Association for Respiratory Care to confirm and monitor endotracheal tube (ETT) placement as well as monitoring for effective chest compressions and return of spontaneous circulation during CPR. In addition to its value in confirming proper ETT placement, capnography may also be useful for trending CO₂ levels during ventilator management.

With the advent of newer technology which allows for improved sampling in non-intubated patients including neonates, capnography is rapidly growing in use in many non-intubated applications where adequacy of ventilation may be compromised. These applications include use during procedural sedation, monitoring of patients on opioids or other respiratory depressants, and monitoring for respiratory compromise in patients both within and outside the hospital setting.

Capnography is measured using two primary methods. Mainstream capnography measures CO₂ by placing a sensor chamber directly in the breathing circuit, attached at the ETT and provides a graph of the CO₂ concentration against volume. Sidestream capnography measures CO₂ by drawing a sample of the breath from the breathing circuit to the sensor within the monitor and plots a CO₂-time capnogram. Each offers advantages which are summarized in Table 1. Microstream technology is an innovation of sidestream technology which uses a CO₂-specific IR wavelength that is unaffected by the presence other gases (ie O₂, N₂O, He or inhaled anesthetics). Other capnography technology requires correction for these gases or may report inaccurate results. Additionally, Microstream permits the use of a very low sample flow rate (50 ml/min), minimizing removal of tidal volume (Vt) which is important in neonates.

<table>
<thead>
<tr>
<th>Mainstream</th>
<th>Sidestream</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Advantages:</strong></td>
<td><strong>Advantages:</strong></td>
</tr>
<tr>
<td>1. Some devices provide estimates of dead space (Vd/Vt)</td>
<td>1. Less weight/obstruction on the end of the ETT which may reduce the potential for kinking and migration/extubations and improve patient comfort</td>
</tr>
<tr>
<td>2. No removal of air from Vt to sample for measurement</td>
<td>2. No external exposure of expensive sensor to damage/replacement</td>
</tr>
<tr>
<td>3. Easy to use with intubated and non-intubated applications</td>
<td>3. Easy to use with intubated and non-intubated applications</td>
</tr>
</tbody>
</table>

**Capnography in Intubated Infants**

In patients with normal ventilation to perfusion (V/Q) matching, the etCO₂ is generally 2-5 mmHg less than the arterial CO₂ (PₐCO₂). When V/Q mismatching occurs secondary to changes in dead space or perfusion, this gradient widens; however, McSwain et al found that the correlation of etCO₂ to PₐCO₂ remained strong at all ranges of increasing dead space. McSwain states, “In patients with a Vd/Vt ≤ 0.40 there was an excellent correlation (p=0.95) between PetCO₂ and PaCO₂. Though the strength of the association diminishes slightly as Vd/Vt increases, the correlation remains strong (p=0.86) even at Vd/Vt of 0.56-0.70, and moderately strong (p=0.78) at Vd/Vt > 0.7. Thus, PetCO₂ appears to be a useful indicator of PaCO₂ even in patients with substantial lung disease, provided that the expected increase in the PetCO₂-PaCO₂ difference is taken into consideration.”

In a review of publications to explore the value of end-tidal carbon dioxide in ventilated neonates, Naidu found that all the studies in this review showed that a correlation exists between etCO₂ and PaCO₂. However, this correlation was stronger in the groups with no underlying lung disease. Naidu concluded that while etCO₂ cannot replace ABGs, it can be used as a valuable trending tool understanding the impact of gradient.
etCO₂ Sampling at the Carina

Kugelman et al explored an innovative method of sampling etCO₂ at the carina through the use of an endotracheal tube (ETT) with a monitoring lumen (Figures 1 and 2),¹¹ which may be less affected by the ventilator circuit flow and leaks around the uncuffed ETTs, thus improving the correlation with PaCO₂.¹²,¹³ Kugelman states “Since 2008 and even before, we have used the double lumen ET tube and Microstream capnography monitoring as a routine in our unit. We continue to use it routinely for other studies and during routine care within the department and in the delivery room. I would say that in 80 to 90% of the infants we use Microstream capnography monitoring via the double lumen tube. We have good agreement between etCO₂ and PaCO₂ for most infants; etCO₂ is typically two to five millimeters of mercury lower than PaCO₂ for most babies. For infants where the gradient is higher, such as those with higher ventilation/ perfusion mismatch, we get an idea of the agreement and as there may be fluctuations as the baby’s condition changes, we still periodically check the blood gas to ensure the gradient is staying relatively consistent.”

In their study of 27 infants which included analysis of 222 and 212 measurements of end-tidal CO₂ at the carina and ETT connector respectively, carinal end-tidal CO₂ had a better correlation with PaCO₂ and a better agreement with PaCO₂ than etCO₂ sampled at the ETT connector. In patients with significant lung disease (PₐO₂/PₐCO₂ ratio < 0.3), the gradient between carinal etCO₂ and PaCO₂ increased, but the bias remained < 5 mm Hg. The average agreement with PₐCO₂ was -1.5mmHg.

More recently, Kugelman used this same sampling method in infants using high-frequency ventilation (HFV).¹⁴ Sixteen premature infants with a median gestational age of 26.5 weeks were ventilated with HFV. Analysis included 195 measurements and the correlation of carinal etCO₂ with PaCO₂ (r = 0.68, P < 0.0001) and the agreement (bias ± precision: -2.0 ± 10.7 mmHg) were adequate. They concluded that continuous integrated etCO₂ measured at the carina is feasible in HFV, has adequate correlation and agreement with PaCO₂ and can be helpful for trends and alarm for unsafe levels of PaCO₂ in premature infants ventilated with HFV.

Capnography in Non-Intubated Infants

In a study of the performance of capnography in non-intubated infants by Coates et al, the correlation of sidestream CO₂ with ABG was excellent (r² = 0.907).¹⁵ Results were not significantly altered when weight and respiratory rate were added as independent variables. Bland-Altman analysis revealed a bias of -2.7 with a precision of ±6.5 when comparing sidestream CO₂ to ABG.

In a retrospective study, Moses et al investigated the correlation and level of agreement between end-tidal carbon dioxide and venous CO₂ (PvCO₂) in non-intubated pediatric patients with moderate to severe respiratory distress.¹⁶ EtCO₂ was correlated highly with PvCO₂ in non-intubated pediatric patients with moderate to severe respiratory distress across respiratory illnesses. They concluded that although the level of agreement between the two methods precludes the overall replacement of blood gas evaluation, etCO₂ monitoring remains a useful, continuous, non-invasive measure in the management of non-intubated children with moderate to severe respiratory distress.

Summary

Capnography can play an important role in the management of both intubated and non-intubated infants in providing a continuous trend of CO₂. Sampling at the carina may play a role in improving the correlation of end-tidal and arterial CO₂. It is important for the clinician to clearly understand the benefits and limitations in the use of the technology, as well as factors that impact the gradient between end-tidal and arterial CO₂.

References

FROM NEONATE TO ADULT, YOUR PATIENTS COUNT ON YOU.

Microstream capnography monitoring helps you detect subtle, but clinically significant variations in your patient’s breathing. This means if your patient shows signs of respiratory compromise, you can respond faster and provide earlier intervention.

- Intubated and non-intubated CO₂ continuous monitoring
- 50ml/min sample size for measurement of CO₂ partial pressure
- CO₂-specific algorithm for enhanced accuracy
- Ability to accurately detect up to 150bpm for CO₂ qualified respiration rate
- Smart alarm management technology

Visit our website to learn more about respiratory compromise:

www.covidien.com/rms/clinical-solutions/respiratory-compromise


9 McSwain SD, Hame DS, Smith PB, et al. End-tidal and arterial carbon dioxide measurements correlate across all levels of physiologic dead space. Respir Care 2010;55(3):288-293


**Can Weekly Antepartum Testing Decrease Near Term and Term Stillbirth?**

M Terrani, MD, F Gonzales, MD, J Korman, MD, A Dillon, RDMS

**Introduction**

In industrialized countries, there is an expectation that every pregnancy will end with the birth of a healthy child. Yet, one fetus out of 200 is stillborn. Sudden fetal death syndrome, also known as stillbirth, continues to be an emotionally devastating outcome for both parents and caregivers. The global burden of stillbirth is estimated at 3.2 million fetal deaths every year worldwide. In the USA, the mortality rate from stillbirths is equal to that from prematurity and sudden infant deaths combined.¹ Frets, et al ² conducted a study to compare three strategies for the prevention of stillbirth in women aged 35 years and older, who were provided standard care; namely, no antepartum testing or induction before 41 weeks, weekly testing at 37 weeks with induction after a positive test, and no testing with induction at 41 weeks. This study showed that without a strategy of antepartum surveillance between 37 and 41 weeks, women over 35 years old will experience 5.2 unexplained stillbirths per 1000 pregnancies. Weekly antepartum testing initiated at 37 weeks would avert 3.9 stillbirths per 1000 pregnancies.²,³ Since the majority of patients experiencing stillbirth are younger than 35 years of age, the purpose of this study was to assess if weekly antepartum testing can decrease stillbirth rate in all age groups as well.

**Materials and methods**

Our antepartum testing model (full biophysical profile weekly from 36 weeks on) started with a cohort of 6900 women over a 10-year period (2006-2016). Patients who experienced stillbirth prior to the onset of testing were excluded. Biweekly testing was used in high-risk patients using standard indications. A positive test served as an indication for delivery (induction of labor or cesarean section). Women with a negative test result remained undelivered until a subsequent positive test or the onset of labor. The control group consisted of 4420 patients for whom antepartum testing was performed using indications proposed by ACOG. The following parameters were analyzed: the stillbirth rate per 1000 births and the total number of inductions needed to avert a single stillbirth. Stillborns with congenital anomalies and lethal chromosomal and genetic syndromes were excluded. A number of cesarean sections were not included because some were performed on maternal demand. Only deliveries, which took place after 36 full weeks, were included in both groups. All statistical computations were performed using DATA 4.0; Trec Age software, Williamstown, MA). All statistical tests were two-sided and a probability value of <.05 was considered statistically significant.

**Results**

Without a strategy of weekly antepartum fetal surveillance between 36 and 41 weeks, women of all age groups experienced 1.6 stillbirths per 1000 pregnancies. For women undergoing weekly testing, the stillbirth rate was 0.9 per 1000.

Obstetrical statistics related to weekly antepartum testing is reflected on Tables 1 and 2.

<table>
<thead>
<tr>
<th>Table 1. Effect of unexplained stillbirth risk on outcomes of weekly antepartum testing initiated at 36th week of gestation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal deaths per 1,000</td>
</tr>
<tr>
<td>Fetal deaths averted</td>
</tr>
<tr>
<td>Tests per pregnancy</td>
</tr>
<tr>
<td>Tests per fetal death averted</td>
</tr>
<tr>
<td>Inductions per fetal death averted</td>
</tr>
</tbody>
</table>

**Table 2. Individual data on stillbirth in the study group**

<table>
<thead>
<tr>
<th>Mother's Age</th>
<th>Gravity</th>
<th>GA (if available)</th>
<th>Pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. 31</td>
<td>G₂P₁</td>
<td>37 weeks</td>
<td>N/A</td>
</tr>
<tr>
<td>2. 36</td>
<td>G₂P₁</td>
<td>36 weeks</td>
<td>N/A</td>
</tr>
<tr>
<td>3. 30</td>
<td>G₂P₁</td>
<td>35 plus weeks</td>
<td>Placental abruption</td>
</tr>
<tr>
<td>4. 30</td>
<td>G₂P₁</td>
<td>35 plus weeks</td>
<td>Placental abruption</td>
</tr>
<tr>
<td>5. 36</td>
<td>G₂P₁</td>
<td>39 weeks</td>
<td>N/A</td>
</tr>
<tr>
<td>6. 41</td>
<td>G₂P₁</td>
<td>36 weeks</td>
<td>Hemorrhagic vasculopathy</td>
</tr>
</tbody>
</table>

**Table 3. Distribution of stillbirth rates per week of gestation and number of inductions per fetal death averted**

<table>
<thead>
<tr>
<th>Outcome*</th>
<th>36</th>
<th>37</th>
<th>38</th>
<th>39</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fetal deaths per 1,000</td>
<td>0.4</td>
<td>0.2</td>
<td>0.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Inductions per fetal death averted</td>
<td>14</td>
<td>18</td>
<td>31</td>
<td>38</td>
</tr>
</tbody>
</table>

*Fetal deaths averted per 1000 pregnancies compared with no testing.
**Discussion**

In the USA, the prevalence of stillbirth is about 1 out of 200 pregnancies for Caucasian women and 1 out of 87 for African-American women. In an attempt to address the problem, Fretts et al² focused on older women because these women are at higher risk of stillbirth and have fewer reproductive opportunities. They concluded that compared with no testing, a policy of weekly antepartum testing beginning at 37 weeks of gestation in women aged 35 years and older, results in a reduction in unexplained fetal deaths. Labor induction reduces stillbirth, but it may also increase the risk of cesarean delivery, which is already on the rise in this older age group.

Recently, Walker et al⁴ conducted a randomized trial of labor induction in women over 35 years old. The primary outcome was a cesarean delivery. The trial was not designed or powered to assess the effects of labor induction on stillbirth. Induction at or before the due date in women 35 years of age or older may be beneficial because the gestational age at delivery that is associated with the lowest cumulative risk of perinatal death is 38 weeks. However, induction itself also carries risks (eg, cord prolapse, uterine hyperstimulation, etc). Results of the trial showed that among women of advanced maternal age, induction of labor at 39 weeks of gestation, as compared with expectant management, had no significant effect on the rate of cesarean section and no adverse short-term effects on maternal or neonatal outcomes.

Our practice of performing weekly antepartum testing starting at 36 weeks until delivery in all pregnant women, was instituted in 2006 because the majority of all stillbirths occur in young, low-risk patients. Women with known risk factors for stillbirth (obesity, diabetes, growth restriction, smoking, etc) are routinely subjected to frequent antepartum testing according to ACOG recommendations.

Similar to the results obtained by Fretts, et al² in older women, we also observed decreased stillbirth rates in patients of all age groups when weekly antepartum testing was applied. It fell from 1.6 per 1000 births to 0.9 per 1000 births. Recent policies limiting elective deliveries to 39 weeks and beyond which have been supported by ACOG and enforced by most hospitals have further increased the importance of this enhanced testing regimen. Patients should be aware that, in spite of the additional cost of testing and its effects on induction and operative delivery rates, weekly fetal assessment decreases the term stillbirth rate in all age groups significantly. In conclusion, the practice of weekly antepartum surveillance should be applied to all age groups in order to decrease the overall rate of near-term and term stillbirth.

**References**


2. Fretts RC, Elkin E, Myers E, Heffner J. Should older women have antepartum testing to prevent unexplained stillbirth? Obstet Gynecol 2004; 104: 56-64.


Case report
A 41 year-old primigravida with long-term history of infertility arrived to New York as an international patient for elective cesarean section, which is not offered in her country without obstetrical indications. She was placed on weekly fetal surveillance and requested that surgery be performed at 38+ weeks of pregnancy with an amniocentesis if indicated. A well-known New York hospital declined to perform the surgery at the time requested by the patient and her doctor in accordance with its policy not to perform elective cesarean delivery procedures until the fetus reached 40 complete weeks. Fetal demise was detected at 39 weeks; the patient returned to country of origin to deliver a stillbirth vaginally. No further information eg, cause of death, placental pathology, etc was available.

Comments
In a 2010 manuscript, Clark et al,\(^1\) stated that the practice of elective delivery at 39 weeks is common in the United States despite long-standing recommendations by the American College of Obstetricians and Gynecologists (ACOG) against this practice.\(^3\) Such policies are supported by both the desire to decrease neonatal morbidity and the desire to avoid cesarean sections resulting from failed inductions due to an unripe cervix. A detailed analysis of perinatal outcomes by week of gestation was performed by Cheng et al.\(^3\) This study focused on a population of low risk women who delivered at term in the United States. In these women, pregnancy complications differed by gestational age at delivery. The risk of operative delivery and maternal morbidity is lowest between 37 and 39 weeks of gestation and begins to increase at 40 weeks. Some of the neonatal morbidities exhibit a similar pattern of rising with gestational age beyond 39 weeks (eg, macrosomia and meconium aspiration), others continue to decrease beyond 39 weeks of gestation (eg, RDS).

Our data is derived from a collection of vital statistics obtained from delivery summaries in 1,200 consecutive patients that have been compiled in Table 1. Using a ranking analysis methodology, Table 1 illustrates the most common maternal and fetal complications in order of frequency for various gestational ages. Elective deliveries were performed upon the patient’s request with consenting physician starting at 38 plus weeks of pregnancy. We were interested in maternal and fetal outcomes including:

<table>
<thead>
<tr>
<th>Gestational age at elective delivery</th>
<th>Maternal complications</th>
<th>Fetal complications</th>
</tr>
</thead>
</table>
| 37-38 weeks                         | Cesarean section due to failed inductions | ICU admission  
Need for mechanical ventilation  
Low Apgar score |
| 38.1-39 weeks                       | Perinatal lacerations | Macrosomia  
Neonatal injury  
Stillbirth |
| 39.1-41 weeks                       | Obstetrical hemorrhage | Oligohydramnios  
Macrosomia  
Neonatal injury  
(including shoulder dystocia)  
Meconium aspiration  
Stillbirth |

Overall, while the frequency of various complications varies, there is no clear diminishment of overall complications between 38 and 40 weeks of gestation. Furthermore, no variation in long-term morbidity or mortality was detected in that range. This seems troubling in the context of the ACOG Committee opinion and the manuscript of Clark et al\(^1\) which seem to insist on a clear lack of cognizable benefits associated with elective birth prior to 39 weeks. While Clark et al\(^1\) denies an increase in stillbirths associated with a prohibition of elective cesarean sections before the 39th week, he does acknowledge that the net rate of stillbirths would increase if the population studied is adequately large.\(^1\)
The following parameters were used to justify ACOG’s policy limiting the patient’s right to choose and the obstetrician’s right to suggest the time of the patient’s delivery:
1. Increased rate of RDS
2. Increased rate of NICU admissions
3. Increased need for mechanical ventilation
4. Low Apgar scores

Our data agrees that RDS rates and the need for mechanical ventilation in newborns decreases with advancing gestation. However, in the vast majority of cases, no long-term ventilation was required. In our experience, no long-term respiratory problems were detected in babies born at 37 and 38 weeks of pregnancy. The criteria for both NICU admissions and Apgar score are subjective parameters. Some hospitals have policies to admit all 37-week neonates for observation and doctors tend to assign lower Apgar scores to newborn delivered before their due dates. Neither higher rates of asphyxia nor increased frequency of cerebral palsy have been reported in 37-week newborns in comparison to 39 and 40-week neonates.

Most would agree that the most serious issue in late-term gestation is the risk of stillbirth. It is obvious that the rate of stillbirth doesn’t stop between 37 and 39 full weeks of pregnancy. The risk of stillbirth after 32 weeks of gestation increased with gestational age, and half of these late fetal deaths occur at near term.6,7

Because of the increased prevalence of oligohydramnios, umbilical cord accidents, fetal growth restriction, placental insufficiency with advancing pregnancy, the rate of stillbirth increases. Although there are no clearly identifiable risk factors for stillbirth, advanced maternal age puts fetuses at risk.7,8 Frequent antepartum testing was shown to decrease stillbirth rate from 5.2/1000 to 3.9/1000 in the advanced maternal age group.9 Stuck with the hospital’s inflexibility with mandatory 39 week elective delivery rule, Terrani et al10 designed a special protocol of universal weekly antepartum testing. Their antepartum testing model (biophysical profile weekly at 36 weeks on) started in a cohort of 6600 women. Women with a negative test remained undelivered until the subsequent positive test or onset of labor. Control group consisted of 4420 patients in whom antepartum testing was performed using indications accepted by ACOG. A strategy of weekly antepartum testing starting at 36 weeks of pregnancy in women of all age groups reduced the number of stillbirths by 58%.9

The immediate negative impact of the implementation of “39 week rule” had been also reported by Nicholson, et al10,11 Investigators found that there was a significant increase in the proportion of term stillbirths after the adoption of the rule; from 2007 to 2009, the proportion was 1.103 per 1000 deliveries, whereas from 2011 to 2013, it was 1.177 per 1000 (relative risk [RR], 1.07; 95% confidence interval, 1.038 – 1.096).10,11 Such changes were more pronounced in larger states. In Ohio, for example, a “significant and clinically important increase” was observed, from 1.04 per 1000 deliveries before the rule was adopted, to 1.26 per 1000 deliveries after (RR, 1.21). Continuous distribution is seen across time, with regression line that has a P value of .034. The slope of the change is an increase of 0.0186 per 1000 deliveries per year. “Given an increase of 0.0186 per 1000 per year, given six yearly intervals from 2007 to 2013, and assuming 3.4 million term births per year in the United States, there could be 335 more term stillbirths in 2013 than in 2007.”11

It is likely that this figure would actually be greater if it were not for the confounding factor of deliveries generally shifting from 40 to 39 weeks.11 Thus, it seems that a substantial portion of the increase in stillbirths during the period analyzed can be attributed to the 39-week rule.

When considering the manuscripts of Clark, et al1,4 what might be more troubling than the purely medical contentions are the policy prescriptions that the research is used to support. The authors advocate for a “hard stop” approach insisting on a policy that would prohibit elective inductions and cesarean deliveries at less than 39 weeks of gestation. This policy would be mandatory and would be enforced by hospital staff members who would prohibit doctors from performing any such deliveries. Furthermore, any “questionable “indications” would be handled in the standard manner by accessing chain of command.”1 This, essentially, amounts to a blanket prohibition of the practice.

Not surprisingly, it was found that this lead to a substantial decrease in elective deliveries before the 39-week mark. What is more interesting is that the study also attempted two other methodologies for decreasing the frequency of elective deliveries before the 39-week mark. Some facilities implemented the “soft stop” approach, whereby a policy discouraging elective deliveries before 39 weeks of gestation would be discouraged, but individual attending physicians would be permitted to perform the procedure if the patient and the physician so decided. All such cases, however would be referred to a peer review committee for evaluation. A third group of facilities were merely provided with professional literature related to such procedures and advised against performing them. In both of these groups, some decrease in the rate of elective deliveries before the 39-week mark was detected. However, the decrease in the “soft stop” cases, while statistically significant, was substantially smaller than that detected when the “hard stop” method was implemented. The education only method yielded an even smaller decrease which was not statistically significant.1

Clark, et al1 interpret the smaller decreases as documentation that education alone is ineffective in “changing that practice of many obstetricians” and that this “demonstrate[s] how far the specialty has to go in embracing the concept of evidence-based (as opposed to anecdotal experience-based) practice.” In doing so, Clark, et al1 attribute the persistence of the practice of elective pre-39 week deliveries to the rejection of evidence-based practice by those practitioners who persisted in performing such deliveries. It is likely that some of the practitioners, despite clear awareness of the literature and, in the case of the “soft stop” method, substantial additional hurdles, persisted in performing such procedures because of a consciousness and willful rejection of the evidence to which they were exposed, or for other potentially inappropriate reasons.

Implicit in the logic of the argument in Clark, et al1,4 is an ethical judgment that the primary considerations at issue are morbidity and NICU admissions. However, one important issue that is ignored is the distinction between short-term and long-term morbidity. While Clark, et al,1,4 cite multiple studies indicating that pre-39 week deliveries are associated with higher rates of morbidity, none of these studies seem to distinguish between the two types of morbidity.

In addition to failing to consider the distinction between different sorts of morbidity, the logic of the argument depends
on a particular ethical judgment as to how morbidity and mortality ought to be balanced. In fact, Clark, et al.\(^4\) explicitly acknowledge that prohibiting elective pre-39 week deliveries will certainly increase stillbirths, but contend that such increase will be minimal. Further they contend that anyone who feels that this risk is of adequate importance to counterbalance the interest in minimizing morbidity that is achieved by prohibiting elective pre-39 week deliveries, must support a policy of broadly mandating pre-39 week deliveries.

However, this line of reasoning is only coherent if one approaches the question from the perspective of implementing a mandatory policy. When viewed from the perspective of a policy-maker implementing mandatory policies that will be binding on all practitioners and all patients, the logic makes sense and individual circumstances cannot be appropriately addressed. However, when viewed from the perspective of an individual decision-maker, be it an obstetrician or a patient, the ability to make an individual decision in accordance with one’s ethical and aesthetic values and preferences lies at the core of patient autonomy. In situations where a universal judgment as to relative values that stand in competition to one another is elusive, the default course of action is, and ought to be, to allow individual stakeholders to make their own determinations, so long as they are adequately informed as to all the risks associated with the decision.

It is important to also consider the fact that not all harm is physical. The psychological trauma experienced by a mother resulting from a stillbirth can be tremendous and far reaching.\(^12\) While there has been some focus on dealing with these psychological harms, for example a study by Cacciatore et al.,\(^13\) found that there was a statistically significant psychologically therapeutic effect of mother's holding their stillborn babies, there has not been enough focus on addressing this substantial problem because medical professionals are still focusing their attention on understanding and preventing stillbirths and miscarriages. The profound psychological trauma that afflicts mothers who suffer from stillbirths must be carefully considered in the scope of developing policy prescriptions for measures that might affect them.

Autonomy is a central value in modern medical ethics and policymaking. While certain procedures, obviously, can and should be strictly proscribed, the decision to do so should not be taken lightly and the threshold to be met ought to be quite high. The decision whether or not to pursue pre-39 week delivery does not come close to meeting this threshold. The risk of stillbirth and other complications which increase as gestation progresses are not so clearly outweighed by the alternative birth complications and the greater net short-term morbidity which are more prevalent in relation to pre-39 week deliveries. Hospital administrators and insurance companies should not be empowered to make decisions that are binding on all patients and healthcare providers. In a matter of such complexity, there is no single balance that is right for everyone and the only appropriate authority to make a final decision is the patient in close and involved consultation with her obstetrician, who is most intimately familiar with her needs and preferences.

**References**

A Safe Pressure Relief Gel Device for Patients in the Neonatal Intensive Care Unit

Chrysty Sturdivant, OTR; Sandra Carroll, OTR; Genna Stone, RN, RNC-NIC, MBA; Mustafa Suterwala, MD

Abstract
Extracranial pressure applied to the occiput of a neonatal and especially a preterm patient can lead to cranial molding including deformational plagiocephaly (DP) and pressure ulcers (PUs). Managing this extracranial pressure either through repositioning or pressure reduction devices is part of clinical care in the neonatal intensive care unit. A new device intended to reduce the pressure applied to the occipital region of an infant’s cranium was tested in a clinical setting. The device was evaluated for its potential to cause skin irritation and excessive perspiration, as well as for its ability to remain on the patient’s head during normal movement. No adverse events, such as skin irritation, were noted, and the pressure relief device remained securely on the infants’ heads throughout the study. This pressure relief device may be a useful tool to mitigate risks associated with external pressure applied to the skull of a neonatal infant.

Keywords
deformational plagiocephaly (DP), cranial molding, pressure ulcers, neonatal, back to sleep, pressure reduction, extracranial pressure, neonatal intensive care unit

Introduction and Purpose
Extracranial pressure applied to the head of an infant over time can result in deformational plagiocephaly (DP) or a pressure ulcer (PU) or both. DP is an asymmetrical posterior flattening of the head that is not caused by craniosynostosis or premature suturel fusion.1 DP in infants is a significant clinical issue. The prevalence of this condition across the broad population has been reported at about 19% to 30%,2,3 although Mawji et al. have reported a rate greater than 46%.4 The variation may be due in part to using different criteria to define DP; eliminating the subjects with the mildest degree of DP in the population of the Mawji study yields a prevalence of about 23%, similar to the other findings. In a study of 380 full-term children, it was found that 84 had plagiocephaly at seven weeks. Of these, 75 (19.7%) did not have plagiocephaly at birth implying that environmental conditions were responsible for the cranial deformation.5

Interpolating from US Census figures indicates that as many as four million infants under one year of age may be affected.6 Very preterm infants may be particularly at risk for DP, with 23% having moderate to severe DP, while in the subset of very preterm infants (less than 32 weeks gestational age) 38% have of moderate to severe DP.8

A goal of clinical care in the neonatal intensive care unit (NICU) is to manage the pressure applied to the head of the patient to help allow the rapid growth of the neonatal brain to fill out the cranium evenly.9 Several approaches are employed by clinical staff to avoid consistent high pressure on the cranium including manually repositioning the patient and trying to keep the head of the patient on a padded device.10 This is especially important when the patient has very limited head movement such as in the case of neurologic diseases or difficult airways.9

DP has implications for quality of life. Numerous studies highlight the nature and extent of the distinct cranial deformities that can occur, ranging from facial asymmetry, astigmatism, malocclusion of the jaw, otitis media, and malposition of ears to statistically significant dimensional differences of the brain as measured by MRI.11-13 It is speculated that these anatomical changes can have lasting effects including impaired hearing associated with otitis media raising concerns for “language, speech, and cognitive developments”14 and misaligned primary dentin associated with plagiocephaly increasing the prevalence of orthodontic abnormalities.15

Pressure ulcers are also related to sustained pressure to soft tissue, especially over a bony prominence. Prevalence rates for PUs in neonatal intensive care units (NICUs) have been reported as 23%.16 Similar rates are reported in pediatric intensive care units (PICUs). In a study of three PICUs, 86 of 322 patient studied (27%) developed PUs.17 Rates of PUs with pediatric patients tend to be higher in intensive care units than on other units.18 In this population, the head is a common location of these pressure ulcers.19-23

The purpose of this study was to evaluate the safety of a new cranial pressure relief device (GELShield, Invictus Medical, Inc, San Antonio, Texas) intended to reduce the pressure applied to the head of a recumbent infant. The secondary purpose was to evaluate the pressure relief device’s ability to remain on the heads of patients during normal movement. This study considers issues with the integrity and irritation of the skin that contacts the device, and instances of the device becoming displaced; it also notes the ease of application of the device on the patient.

Materials and Methods
The study protocol was reviewed and approved by the Institutional Review Board of Baylor University Medical Center. A prospective, single-site I safety trial was conducted on 42 consecutive patients admitted to the NICU at Baylor.
Before placing the pressure relief device on the head of the subject, the investigator evaluated the infant’s head using the Skin Appearance Assessment Score tool. After placing the pressure relief device on the infant’s head at baseline, subsequent assessments of skin appearance using the Skin Appearance Assessment Score tool, as well as assessments of excessive perspiration, were made at 15 minutes, one hour, three hours, and six hours after baseline. After six hours, the pressure relief device was removed from the subject’s head. Two hours after device removal, a final evaluation was made with the Skin Appearance Assessment Score tool. After the pressure relief device was removed from the subject, it was secured in a storage area and was not reused on another patient per the manufacturer’s instructions for use.

Results
Forty-two patients were enrolled in the study, and one subject was withdrawn after the one-hour assessment. The gestational ages of the subjects ranged from 33 weeks, 3 days to 40 weeks, 3 days (mean = 35 weeks, 3 days), while the chronological ages of the subjects ranged from 5 to 94 days (mean = 24.6 days). Of the 42 subjects, 20 were male. Head circumference ranged from 28.0 cm to 34.3 cm (mean = 30.6 cm).

No AEs (Skin Appearance Assessment Score > 2) were reported throughout the study. All baseline Skin Appearance Assessment Scores were 0. Following baseline, a total of 208 assessments were made at the four periods during which the pressure relief device was worn and the one period after the device had been removed. The scores recorded at all time points are shown in Table 2. None of the skin redness noted (score of 1 or 2) was non-blanching erythema. These scores and those of the baseline assessment are summarized in Figure 2.

Excessive scalp perspiration was evaluated at each of the four time points during which the pressure relief device had been worn. Of the 166 observations for excessive perspiration, one observation (<1%) at six hours was deemed to be excessive. At no point in the study did the pressure relief device become dislodged from the head of any subject while the infant was lying in the crib.

Discussion
The executed six-hour study comprising one three-hour period of continuous use of the pressure relief device was designed to match the NICU standard of care practice of handling and examining infants at least every three hours. Neonatal nursing protocols state that periods of needed, undisturbed rest be...
provided for the infant, but that these periods usually do not extend beyond three hours so that appropriate assessments and interventions can be completed. The duration of the study period was selected to accurately mimic actual clinical care.

The use of the device did not interfere with our routine clinical care of the infant. No monitoring modality was adversely affected, our routine inspection of the patient’s skin was unaffected, and the device was sufficiently stable on the infant’s head that the clinicians did not have to reposition the device between skin assessments.

While the AAP’s “Back to Sleep” guidelines may have originally been directed to parents’ caring for their infants, NICUs have also established protocols to implement these guidelines, including providing firm sleeping surfaces and supine sleep positioning prior to hospital discharge. In part because of the hydrogel layer in the occipital cup portion of the pressure relief device, the peak pressure experienced in the occipital region is likely to be reduced, especially when the infant is in the supine position, the prevalent position recommended in the NICU to facilitate, for instance, mechanical ventilation when airway management is critical or as part of an intraventricular hemorrhage-prevention protocol. All factors taken together, a mechanism to alleviate the pressure on the occipital region would be useful.

Specific guidelines for managing and preventing pressure ulcers prescribe several practices for which use of the pressure relief device may be beneficial. For instance, a gel or a foam material. The pressure relief device promotes both of these techniques, enveloping the head of the infant, providing an easy means of rolling the infant’s head from one side to the other based on clinical judgment, and maintaining the layers of foam and gel found within the pressure relief device between the head of the infant and the mattress. The second prong is to provide pressure relief or attenuation. According to the consensus document, this is accomplished by providing a pressure-redistributing support surface, such as an overlay on an existing mattress. The pressure relief device is in essence an overlay system that travels with the infant’s head, providing the same type of pressure relief by increasing the contact area between the infant and the surface with which it is in contact.

While mobility, perfusion, and pressure over time are the most important risk factors for pressure ulcers, skin moisture is another predictor. In the current study, only one instance of perspiration was noted under the pressure relief device, and this occurred after three hours of continuous application, the time at which the device would typically be removed per the instructions for use to allow the healthcare provider to wipe away moisture. The clinicians executing the study did not detect any alteration in neck position while the device was used on the infants.

One limitation of the study was limiting the number of users to the three trained investigators. This was done to help ensure consistent application of the device however, a broader range of users may have found variations in skin response secondary to differing application techniques. Also related to application technique, the circumferential pressure of the device on the infant’s head was dictated by the experienced perception of the trained investigator using the manufacturer’s recommended application technique rather than being confirmed by a pressure sensor oriented between the device and the infant’s skin. Such a pressure sensor could have confirmed consistent circumferential pressure however. Another limitation of this study was the lack of long-term assessment of the effect of the device on cranial molding during an infant’s stay in the NICU. However, we believe that the pressure-reduction attributes of the construction of the pressure relief device would help deter cranial molding. In theory, molding occurs at least in part when cranial growth is resisted in a specific area by an external force. To the extent that this force is reduced by distributing it over a larger area, the resistance to growth should be reduced, thereby decreasing the chance of cranial molding.

In the future, a phase II efficacy study would be appropriate. Such a study could evaluate the trajectory of cranial molding in neonatal patients, tracking any improvements in the change in asymmetry while the patient was being treated in the NICU. The study would have to assiduously avoid any Hawthorne effect in which the staff, recognizing that head shape was being carefully monitored, would change their turning and positioning protocol or technique. A historic control may be one approach to minimize the Hawthorne effect. A consistent application methodology would have to be ensured so the device was not too tight or too loose. Finally, it would be essential to perform a repeatability and reliability evaluation on the cranial deformation measurement. This would ensure that the variability of the measurements did not confound the dependent asymmetry variable. Beyond that, a study comparing this device with currently marketed positioning aids and pillows would be beneficial. This study would also consider secondary endpoints such as the amount of nursing or therapist time required for

### Table 1. Skin appearance assessment score tool (adapted from Maibach and Patrick<sup>19</sup>)

<table>
<thead>
<tr>
<th>Skin Appearance</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No evidence of irritation</td>
<td>0</td>
</tr>
<tr>
<td>Minimal erythema, barely perceptible</td>
<td>1</td>
</tr>
<tr>
<td>Definite erythema, readily visible; minimal edema or</td>
<td>2</td>
</tr>
<tr>
<td>minimal papular response</td>
<td></td>
</tr>
<tr>
<td>Erythema and papules</td>
<td>3</td>
</tr>
<tr>
<td>Definite edema</td>
<td>4</td>
</tr>
<tr>
<td>Erythema, edema, and papules</td>
<td>5</td>
</tr>
<tr>
<td>Vesicular eruption</td>
<td>6</td>
</tr>
<tr>
<td>Strong reaction spreading beyond the application site</td>
<td>7</td>
</tr>
</tbody>
</table>

### Table 2. Summary of skin appearance assessment scores at all time points

<table>
<thead>
<tr>
<th>Score</th>
<th>Baseline</th>
<th>15 min</th>
<th>1 hr</th>
<th>3 hr</th>
<th>6 hr</th>
<th>2 hr post</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>42</td>
<td>41</td>
<td>33</td>
<td>27</td>
<td>28</td>
<td>38</td>
</tr>
<tr>
<td>1</td>
<td>0</td>
<td>1</td>
<td>8</td>
<td>13</td>
<td>11</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>3</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>4</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>5</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>6</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
reorienting the infant on the various devices or other side effects due to movement restrictions and airway management.

Conclusions
The data indicate that the pressure relief device is safe to use on infants in a NICU setting and is unlikely to have any adverse effects on the tissue with which it comes in contact. The use of device was readily accommodated in the clinical care of the patient during the duration of the study and would likely not interfere with routine clinical care over longer periods. The benefits of the force distribution and accompanying pressure reduction of the hydrogel and other materials in the device to a supine infant would be enhanced by the device remaining securely on the infant’s head, as it did throughout the study periods. Further, the security of the device during normal movement should minimize any hazard associated with loose objects in the vicinity of the infant. Thus, this pressure relief device may be a useful tool to mitigate risks associated with pressure applied to the skull of a neonatal infant.

References
Neonatal Research: Great Advances Over Time, But Keep Research Moving Forward

Deb Discenza

In early March, I was honored to attend the 2nd Annual International Neonatal Consortium meeting at the Food & Drug Administration. As the parent of a premature infant and a professional in the community supporting families and educating professionals, it gave me hope to see so many neonatal professionals in one room working to improve neonatal outcomes. Every day on my “Preemie Support” Forum on Inspire.com, I have parents on every continent continually plagued by the very issues being discussed in that meeting. In attendance was Tonse NK Raju, MD, DCH, Branch Chief of the Pregnancy and Perinatology Branch (PPB) of NIH/NICHD. It was wonderful to catch up afterward to ask him his unique view of neonatal research.

Deb Discenza: As a neonatologist that is heavily focused on research—what areas of the NICU research have come a long way?

Dr Raju: From my perspective, it is the entire “perinatal care” that has made a huge advance: these are subtle, but cumulatively, and I believe they have had huge impact on the overall status of preterm infants at birth. This includes infants born as early as 23-25 weeks of gestation, often called “periviable” infants. And, neonatal and obstetric teams have been working together in enforcing general approaches to fetal/maternal management.

The specific areas of major advances are: the use of pulmonary surfactants to reduce the seriousness of respiratory distress syndrome. The drug was introduced to the market in early 1990s, and within a few years nearly a dozen new and improved products have been approved, and their use today is nearly 100% if preterm infants have respiratory distress.

More generalized use of corticosteroids before childbirth in women who come to the hospital in labor and are under 34 weeks of gestation. In the early 1970s, both animal studies and human trials showed that antenatal corticosteroids enhance fetal lung maturation, leads to reduced mortality and lung disease severity, reduces intracranial bleed, and reduces the frequency of necrotizing enterocolitis—as you may know, a very bad infection of the intestines. But, the frequency of use of this very helpful medication until the mid-1990s was less than 20% for eligible patients. In 1994, NICHD organized an expert panel NIH Consensus Conference, which concluded that this treatment is lifesaving. The statement was released on the day of the meeting and a subsequent publication summarized the recommendations. Within a few years, the use of the medication went up to 80—90% among those who deliver preterm babies before four weeks, and there is an appropriate time lag between when the mom gets to the the hospital and when she will have her baby.

The other major area on pulmonary care is the introduction of inhaled Nitric Oxide (iNO) for such conditions as “persistent pulmonary hypertension,” often secondary to meconium aspiration syndrome, congenital diaphragmatic hernia, and often from unknown causes. iNO led to dramatic reduction in infants needing ECMO support, improving their survival, and reducing complications due to this invasive procedure.

The successful campaign for safe sleep—previously called Back To Sleep Campaign—had led to dramatic reduction in Sudden Infant Death Syndrome (SIDS). In fact, it was NICHD with collaboration from AAP that were the leaders in this campaign.

Another one is hypothermia for perinatal asphyxia—dramatic benefits, but still much more needs to be done.

Deb Discenza: What areas of research need better attention?

Dr Raju: We have frequent workshops on many topics, and the findings are published with research agenda. These are publicly available documents in which research agenda is provided for each topic.


Deb Discenza is the mother to a 30-weeker premature baby now almost 13 years old. Ms Discenza is the head of PreemieWorld, LLC and the co-author of “The Preemie Parent’s Survival Guide to the NICU” available at www.PreemieWorld.com.
Are you concerned about oxygen toxicity in neonates?

There are no published national guidelines for hyperoxia management.¹

We appreciate the complexity of the challenges you face every day. That’s why we’re proud to offer OXYGENISADRUG.com, a comprehensive resource with information about:

• Supplemental oxygen therapy
• Consequences of hyperoxia
• Practice and protocols
• Historical perspectives

Though supplemental oxygen is necessary and often beneficial at appropriate doses, elevated levels can put patients at risk for hyperoxia with the potential for long-term tissue damage.²

It is possible to have too much of a good thing. Learn how to manage the challenge at OXYGENISADRUG.com/toxicity

Deb Discenza: Thank you Dr Raju.

Dr Raju: I answer emails or phone calls from scientists around the country who want to apply for NIH grants related to maternal/neonatal topics. As branch chief, I will direct them to appropriate experts in my Branch or to other branches. I also handle most of the calls related to neonatal research. Other aspects of my job include review of progress made by the researchers of funded grants—typically called in the NIH lingo, “management of my grants portfolio.” I attend several major national and international meetings (by the AAP/ACOG/SMFM and so on) to learn the state-of-the-science, and learn about knowledge gaps. This will help me to inform the NICHD and appropriate NIH leadership about the need for stimulating appropriate future research.

Deb Discenza: Where do you hope today’s research will take us say in the next 10 years, 20 years?

Dr Raju: Broad question, but some of the key topics are:

- Eliminating the burden of preterm birth
- Improving brain/eye/heart/lungs/kidney and nutritional outcomes for all newborn infants
- Reducing childhood obesity
Global Network For Women’s And Children’s Health Research: A System For Low-Resource Areas To Determine Probable Causes Of Stillbirth, Neonatal, And Maternal Death

Elizabeth M McClure,1 Carl L Bose,2 Ana Garces ,3 Fabian Esamai,4 Shivaprasad S Goudar,5 Archana Patel,6 Elwyn Chomba,7 Omrana Pasha,8 Antoinette Tshefu,9 Bhalchandra S Kodkany,5 Sarah Saleem,9 Waldemar A Carlo,10 Richard J Derman,11 Patricia L Hibberd,12 Edward A Liechty,13 K Michael Hambidge,14 Nancy F Krebs,14 Melissa Bauserman,15 Marion Koso-Thomas,16 Janet Moore,1 Dennis D Wallace,1 Alan H Jobe17 and Robert L Goldenberg18

Abstract

Background: Determining cause of death is needed to develop strategies to reduce maternal death, stillbirth, and newborn death, especially for low-resource settings where 98% of deaths occur. Most existing classification systems are designed for high income settings where extensive testing is available. Verbal autopsy or audits, developed as an alternative, are time-intensive and not generally feasible for population-based evaluation. Furthermore, because most classification is user-dependent, reliability of classification varies over time and across settings. Thus, we sought to develop classification systems for maternal, fetal and newborn mortality based on minimal data to produce reliable cause-of-death estimates for low-resource settings.

Results: In six low-resource countries (India, Pakistan, Guatemala, DRC, Zambia and Kenya), we evaluated data which are collected routinely at antenatal care and delivery and could be obtained with interview, observation, or basic equipment from the mother, lay-health provider or family to inform causes of death. Using these basic data collected in a standard way, we then developed an algorithm to assign cause of death that could be computer-programmed. Causes of death for maternal (trauma, abortion, hemorrhage, infection and hypertensive disease of pregnancy), stillbirth (birth trauma, congenital anomaly, infection, asphyxia, complications of preterm birth) and neonatal death (congenital anomaly, infection, asphyxia, complications of preterm birth) are based on existing cause of death classifications, and compatible with the World Health Organization International Classification of Disease system.

Conclusions: Our system to assign cause of maternal, fetal and newborn death uses basic data from family or lay-health providers to assign cause of death by an algorithm to eliminate a source of inconsistency and bias. The major strengths are consistency, transparency, and comparability across time or regions with minimal burden on the healthcare system. This system will be an important contribution to determining cause of death in low-resource settings.

Background

Maternal, fetal and newborn mortality rates remain high in low-resource settings [1-3]. A medical cause of death is an important first step in strategy development to reduce these deaths and to measure changes in death rates from specific causes [4-7]. To date, more than 35 systems have been developed to classify the cause of stillbirths alone, and other classification schemes attempt to define causes of neonatal and maternal deaths [8-12]. Most of these classification systems are best suited for high income settings because the tests to define cause of death are extensive. Few of the classification systems are targeted at low-resource settings where more than 98% of deaths occur. In many low-income countries, minimal resources are available for determining cause of death for mothers, much less cause of death for fetuses and newborns which occur much more frequently, and diagnostic tools such as autopsy, placental histology, X-ray, ultrasound and bacterial cultures are generally not available [13].

Dependence on detailed diagnostics makes many of the existing classification systems quite complicated. Many also use several different types of constructs to determine cause of death including primary and secondary causes, associated causes, contributing causes, underlying causes, or preventable causes [9-22]. One system for perinatal mortality, for example, attempts to determine a main cause, an underlying cause and contributing factors [17]. While such systems are useful for research or in areas where the resources are available to determine the many contributions to each death, these systems are too complicated for routine use, especially to ascertain cause of death on a population basis in low-resource settings [4]. The resources required to determine cause of death is important since few of the poorest countries routinely collect cause of death information [14].

The actual cause of death for any individual mother, fetus or newborn is rarely known with a great degree of certainty, especially in resource-poor areas. Some classification systems
have attempted to categorize the degree of uncertainty about whether a specific condition caused a specific death by creating categories such as probable cause, possible cause or whether the condition was merely associated with that particular death [10]. While such systems might also be useful in high resource areas or in specific research projects, they are likely to be too resource-intensive for population-based estimates.

A related issue for classification systems is the percent of deaths classified as of unknown cause. The more certainty required for classification, the greater the proportion of deaths classified as of unknown cause is likely to be. As an example, the percent of stillbirths classified as having an unknown cause varies widely between classification systems. Depending on the classification system [15] and the level of investigation [16], the proportion of unexplained stillbirths has ranged from 15% to more than 70%. Even in high-income countries, with advanced testing and autopsy, a significant proportion of stillbirths are classified as of undetermined cause [9,23].

Other factors important to all classification systems are how the cause of death is determined and who determines the cause of death [23-26]. A major concern with any cause of death classification system is the reliability of the cause of death determination, over time, for the same evaluator(s), and especially for evaluators in different locations, even when the same information is available. When different clinicians determine the cause of death for any specific case, even with the same information available, major differences in the cause of death often occur [25-28]. For example, for a preterm baby with difficulty breathing at birth, the cause of death may be variably classified as prematurity, respiratory distress syndrome (RDS), asphyxia or pneumonia by different classifiers. Similarly, an anencephalic baby who dies in the neonatal period likely dies of the anomaly itself, but also may die from an infection or asphyxia or both. Different classifiers could evaluate these cases and choose very different causes of death. Thus, in most classification systems, the determination of the primary cause of death may not depend only on the case data available but also

---

**Table 1 Causes of stillbirth, neonatal death and maternal death and their hierarchical position in the Global Network Classification System**

<table>
<thead>
<tr>
<th>Classification System</th>
<th>Stillbirth</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal or fetal trauma</td>
<td></td>
<td>Significant maternal trauma especially if the maternal abdomen is involved or there is evidence of fetal trauma takes precedence as a cause of stillbirth over all other potential causes</td>
</tr>
<tr>
<td>Major Congenital anomaly</td>
<td></td>
<td>Major anomaly takes precedence as a cause of death over all other conditions except trauma</td>
</tr>
<tr>
<td>Maternal infection</td>
<td></td>
<td>Maternal malaria or syphilis or signs of amnionitis</td>
</tr>
<tr>
<td>Asphyxia</td>
<td></td>
<td>Based on the maternal or fetal condition noted including obstructed labor, abruption or previa characterized by antepartum bleeding, preeclampsia/eclampsia, fetal distress and cord complications</td>
</tr>
<tr>
<td>Complications of preterm labor</td>
<td></td>
<td>There are some early gestational age stillbirths, generally prior to 24 weeks, where the fetus apparently dies because it is unable to tolerate labor. These very preterm babies are usually not macerated since they usually have died close to delivery</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td>No other cause identified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Neonatal death</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Major Congenital anomaly</td>
<td></td>
<td>Significant congenital anomaly takes precedence as a cause of neonatal death</td>
</tr>
<tr>
<td>Sepsis/pneumonia/tetanus</td>
<td></td>
<td>The presence of these conditions take precedence as a cause of death except when an anomaly is present</td>
</tr>
<tr>
<td>Asphyxia</td>
<td></td>
<td>Breathing difficulties at birth with maternal condition noted including obstructed labor, bleeding, preeclampsia/eclampsia, fetal distress, cord complications, etc.</td>
</tr>
<tr>
<td>Complications of prematurity</td>
<td></td>
<td>Deaths in preterm infants not attributable to other causes. Since it is difficult to differentiate asphyxia from respiratory distress syndrome, we have arbitrarily assigned larger infants with respiratory distress to asphyxia and the smaller or earlier preterm infants to complications of prematurity.</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td>No other cause identified</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Maternal Death</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Significant maternal trauma</td>
<td></td>
<td>Trauma takes precedence as a cause of maternal death</td>
</tr>
<tr>
<td>Abortion/miscarriage/medical termination of pregnancy/ectopic pregnancy</td>
<td></td>
<td>If the subject has a history of abortion or is less than 20 weeks, whether she had hemorrhage, sepsis or other conditions, the cause of death is considered an abortion</td>
</tr>
<tr>
<td>Infection</td>
<td></td>
<td>If there is no trauma or an abortion, the presence of significant infection takes precedence as a cause of maternal death</td>
</tr>
<tr>
<td>Hemorrhage</td>
<td></td>
<td>The most commonly attributed cause of maternal death in most settings</td>
</tr>
<tr>
<td>Hypertensive disease of pregnancy</td>
<td></td>
<td>If mother has a seizure, eclampsia is considered the cause of death. If she has only preeclampsia, other causes may take precedence</td>
</tr>
<tr>
<td>Thromboembolism</td>
<td></td>
<td>With no other obvious cause and sudden onset of severe respiratory distress and chest pain, the cause of death will be attributed to thromboembolism</td>
</tr>
<tr>
<td>Medical condition coincident to pregnancy</td>
<td></td>
<td>If a medical condition such as cancer, cardiac disease, severe anemia, or diabetes is present and there is no other cause of death, the death will be attributed to a medical condition</td>
</tr>
<tr>
<td>Unknown</td>
<td></td>
<td>No other cause identified</td>
</tr>
</tbody>
</table>
because there has been no gold standard for these evaluations, the actual cause of death is often unknown, and which type of provider comes closest to selecting the “true” cause of death is unclear. While physicians have traditionally been viewed as better at determining cause of death than providers with less idiosyncrasies of the classifiers. For this and other reasons, including lack of specific guidelines about how to classify cause of death, there have been large variations in cause of death by the system and evaluators [28-30]. In LIC different types of health care providers may classify causes of death differently [27]. But
training, whether this is the best use of physicians’ or other trained providers’ time is a concern in geographic areas with limited health provider availability.

There are two main types of classification systems, multicausal and single causal [6,30-32]. The multicausal approach lists all potential causes and contributing factors, with rules to distinguish ‘primary’ vs ‘underlying’ or ‘contributing causes.’ This type of system may be more meaningful where resources are available to conduct extensive testing and perform analyses. Another type of system includes a hierarchy to select one primary cause of death, when multiple factors are identified and possibly causal [32]. While a limitation to selecting one primary cause of death is that important secondary or contributing factors or nuances for individual cases may be lost, choosing one primary cause helps to increase the consistency of results and likely makes the data easier to comprehend and use by policy makers [5,33]. Thus in addition to reproducibility of results, a single cause system should allow for more meaningful comparisons in the mortality rates associated with specific causes over time and across geographic areas.

One mechanism to inform cause of death for low-resource settings is based on verbal autopsy (VA) [27,34-37]. VA systems have generally been used for determining cause of maternal deaths. VA requires lengthy family interviews which are a burden on the health system and thus are not practical to conduct on a population-basis. VA for stillbirth or neonatal deaths is more burdensome because they are more frequent than maternal deaths [27]. Furthermore, VA interviews may produce variability in assignment of a cause of death based on the classification system used and the person who assigns a cause of death [27]. Furthermore, in many VA systems, while the clinical information may be gathered in a consistent manner, with few exceptions, a coder determines cause of death, with the limitations of reproducibility noted above [35]. Finally, the diagnostic accuracy of VA has been weak in some field studies, with limited ability to accurately determine some specific causes of death [34,37].

**Methods**

Our objective was to develop reliable classification systems that would assign cause of maternal, fetal and neonatal death using the minimal amount of descriptive data and would not depend upon individual clinicians for the assignment of cause. Our goal is to increase consistency with a low burden on the health system. We elected to use data that are generally available in low-resource settings from the mother, family or caregivers and that require only basic equipment (eg, a scale for birth weight determination, blood pressure cuff, or thermometer). However, with increasing rates of facility delivery in low-resource settings, we also elected not to ignore hospital-based information, if available (eg, chest X-ray diagnosis of pneumonia). We sought to create a system to classify the primary causes of death, that was practical to use and consistent for deliveries occurring at home and other community settings as well as for hospital births. The system described below, the “Global Network Probable Cause of Death Classification” for stillbirth, maternal and newborn mortality was developed within the Global Network for Women’s and Children’s Health Research, a multi-country, research network with sites in Sub-Saharan Africa, Asia and Latin America funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development [38,39].

The underlying principle of the Global Network system was to collect basic and simple observational information related to the pregnancy and death. A second principle was that an algorithm would assign cause of death, removing personal choice or
bias from the assignment. The algorithm uses a hierarchical classification system to determine one primary cause of death. The specific causes of stillbirth, neonatal and maternal death defined by this classification system are shown in Table 1 with the rationale for the hierarchy of the system; these causes align with ICD-10 first level classifications [31], as well as with major existing classification systems. Table 2 includes the specific definitions of each cause, as adapted for this system. The advantage of this methodology is that the system can determine which condition is most immediately associated with the death in a consistent manner across all cases. Although this system may at times classify cause of death differently than other systems, we viewed this possibility as acceptable because there is no gold standard for classifying cause of death, and our system has the attributes of transparency and reproducibility.

The classification system was designed as part of the Global Network’s Maternal and Newborn Health Registry study, a population-based registry of pregnancy which obtains outcomes from consenting women through 6-weeks postpartum [38]. The institutional review boards and ethics committee at the participating study sites (Aga Khan University, Karachi, Pakistan; Kinshasa School of Public Health, Kinshasa, DRC; Moi University, Eldoret, Kenya; San Carlos University, Guatemala City, Guatemala; University of Zambia, Lusaka, Zambia) and their affiliated US partner institutions (University of Alabama at Birmingham, University of North Carolina at Chapel Hill, Columbia University, University of Indiana, Christiana Healthcare, and Massachusetts General Hospital) and the data coordinating center (RTI International) approved the study.

**Results and discussion**

**The stillbirth classification algorithm**

Stillbirths are generally considered to be deaths in utero occurring at 20 weeks gestation or greater, depending on the setting [40]. Among maternal, fetal and neonatal deaths, determining cause of stillbirth has historically been the most challenging type of death to define, as the fetus is not directly observed when death occurs [6]. To date, cause of death in stillbirths has generally been determined from the underlying maternal or obstetric conditions that may be directly or indirectly associated with the fetal death. Additionally, autopsy and placental data may be used to help classify cause of death in stillbirths in high resource settings. At least one high-income country system primarily attributes the cause of stillbirth to maternal or obstetric conditions [16], and placental conditions are considered in many other stillbirth classification systems [41]. However, despite their value in determining cause of death in high-income settings, we have deliberately chosen not to include autopsy and placental findings in this classification system since autopsies are almost never done and placentas are rarely examined histologically in low-income settings.

Where antenatal care is limited and a significant proportion of deliveries occur in home or low-level clinics with community birth attendants [42], distinguishing stillbirth from early neonatal death has been problematic [43]. Thus, some authors have proposed a classification system in which ‘intrapartum death’ encompasses both stillbirths and early neonatal deaths due to intrapartum causes such as asphyxia [44]. To date, no system to determine cause of stillbirth with basic data has been necessary.
The criteria for assigning a cause of stillbirth are shown in Table 2. Our hierarchical method of determining cause of stillbirth relies on a discreet data set. The algorithm first determines whether the stillbirth was associated with maternal or fetal trauma (ie, assault, suicide, accident, fetal trauma); if so, the cause of death is classified as trauma. Second, if trauma did not occur and there is a major (visible) congenital anomaly, the death is categorized as due to congenital anomaly. If neither trauma nor anomalies are identified and signs of infection, and complications of preterm birth, with major congenital anomalies less commonly a cause (by percentage) in low compared to high and middle-income countries.

There are many difficulties in assigning cause of death in neonates even in high-income countries with X-ray, culture and autopsy availability. For example differentiating sepsis and asphyxia is difficult even in term births, while in preterm births where respiratory distress syndrome is a common cause of respiratory failure and death, distinguishing among these three causes of neonatal death is even more difficult.

The criteria for assigning a cause of neonatal death are shown in Table 2. In our system, we first determine if a major congenital anomaly is present (Figure 2). If so, the algorithm assigns congenital anomaly as cause of death. If an anomaly is not present and signs of infection are present (eg, tetanus, omphalitis, sepsis, pneumonia (signs such as late onset respiratory difficulty, fever or hypothermia or X-ray if available), infection is assigned as the cause of death. If neither an anomaly nor infection is present, the algorithm then separates the deaths into those occurring in term or preterm infants. In the term infants, if there were signs of breathing difficulty or no cry at birth, the algorithm assigns the cause of death as birth asphyxia. The maternal or fetal condition likely associated with the birth
asphyxia is noted. If no signs of difficulty breathing at birth or respiratory distress were present, the cause of death is assigned as unknown.

For preterm infants, especially those ≥2000 grams or ≥34 weeks at birth, among those with breathing difficulties or no cry at birth, asphyxia is a common cause of death [46]. In those infants, if breathing difficulty or no cry is present at birth, and maternal conditions such as abruptio associated with asphyxia are present, the algorithm assigns cause of death as asphyxia. Otherwise, the cause of death is assigned to prematurity. If the infant is <2000 grams or <34 weeks at birth, the algorithm assigns the cause of death as being due to preterm birth regardless of whether respiratory distress is present, since RDS is common and pneumonia has previously been considered and rejected as a cause. In infants born at <37 weeks, with no congenital anomaly or infection, the algorithm does not classify any death as of unknown cause, because prematurity is always considered as the primary contributor to death.

Maternal death
Maternal deaths generally are defined as those that occur at any time during pregnancy up to 6 weeks postpartum, regardless of the cause. Maternal deaths are rare compared to stillbirths and neonatal deaths, and fewer classification systems exist to assign cause of maternal death. Furthermore, compared to neonatal deaths or stillbirths, maternal deaths are less likely to have an ‘unknown’ cause of death. However, some reports suggest misclassification of maternal deaths (ie, not recognizing a woman was pregnant at time of her death), with under-reporting of maternal mortality. Maternal deaths have generally been classified as directly or indirectly associated with pregnancy (eg medical causes not brought on or exacerbated by the pregnancy or trauma) [47]. Obstetric conditions directly associated with maternal death include hypertensive diseases of pregnancy (preeclampsia/eclampsia), obstetric hemorrhage (ante or postpartum, with or without severe anemia), sepsis/infection and thromboembolism. Obstructed labor may be associated with maternal death, leading to either hemorrhage or severe infection but the primary cause of death in the current World Health Organization (WHO) international classification system (ICD-10) would be infection or hemorrhage, not obstructed labor. Deaths associated with ruptured uterus are presumed to be secondary to hemorrhage. Conversely, abortion related deaths result from infection or hemorrhage, but deaths occurring at less than 20 weeks gestational age, including from ectopic pregnancy, are classified as abortion related. Indirect causes of maternal death include trauma or medical conditions such as cardiac disease, cancer, or diabetes.

In the Global Network classification system, to assign a cause of maternal death, the major clinical signs and symptoms most often associated with maternal death are identified and defined (Table 2). Next, we developed an algorithm to assign cause of death based on the clinical signs (Figure 3). The algorithm first identifies significant maternal trauma and if present, the cause of death is trauma. If there is no trauma and the pregnancy is less than 20 weeks or an abortion was induced at ≥20 weeks, the cause of maternal death is classified as abortion related. If neither of these is present, and the woman experienced a seizure, eclampsia is considered the cause of death. If none of these are present and any signs of hemorrhage are present, hemorrhage is assigned as the cause of death. If none of the above are present and signs of infection are present, infection is assigned as the cause of death. Next, other signs of hypertensive disease and especially preeclampsia are handled in a similar manner. If at this point, acute shortness of breath and chest pain are present, thromboembolism would be considered the cause of death. Finally, if none of the above are present, the algorithm considers medical conditions not directly associated with the pregnancy, such as renal disease, heart disease, cancer or diabetes, and if any of these are present, the medical condition is assigned as the cause of death. If none of the above is present, the cause of death is classified as unknown.

Conclusions
The Global Network classification system uses minimal, basic data from the mother, family or lay-health providers. No laboratory tests, placental examinations or autopsies are necessary. Easily identifiable signs are noted and collected in a standard way and entered into a database. The cause of death is then assigned by an algorithm. No person assigns the actual cause of death which eliminates a source of inconsistency and bias. Thus the major strengths are consistency and transparency, with an ability to provide comparability across time or regions with minimal burden on the healthcare system. Even if one does not completely agree with the algorithm, the method of assignment is transparent. Also, since all data used to inform the cause of death assignment reside in the database, alterations and/or improvements in the algorithm at a later time will permit reclassification of the cause of death.

The system assigns a single cause of death, although, the algorithm could be altered to select several possible causes if that output is desired. For example, using this system in addition to the primary cause, other conditions that also were present as secondary conditions could be characterized without relying on the subjective judgment of researchers or caregivers. Additionally, other clinical or laboratory questions that might better help to assign cause of death could be added, depending on available resources and the setting where the death occurred. For now, however, we believe that the assignment of a single cause of death is sufficient to guide most public health and medical system policy decisions. More nuanced assignment of cause of death, such as identification of the type of infection that caused a death, would require additional data and is beyond the scope of this system. The system uses the major causes of death that have been well-established, and are commonly used for cause of death classifications, especially in low-resource settings. These attributes make this system potentially useful both for research and public health policy purposes.

We recognize that this system necessarily is a simplification compared to more complicated systems, and subtle and rare causes of death in low-income settings may be missed. It also does not attempt to address social or other factors that may contribute in low-resource settings. Preventable causes of death are not specifically addressed as such. However, with these limitations, the major causes of death related to pregnancy are collected and the portion of deaths attributable to the major causes can be quantified.

We have developed a system to classify causes of death for stillbirth, neonatal and maternal death that should be applicable for low-resource settings. In these areas, where most pregnancy-related mortality occurs, reliable and reproducible classification of maternal, fetal and neonatal death is needed both to advance research and to inform public health strategies to reduce
References


Antimicrobial therapy in neonatal intensive care unit

Chryssoula Tzialla, Alessandro Borghesi, Gregorio Serra, Mauro Stronati and Giovanni Corsello

Abstract
Severe infections represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year. Antibiotics are the most commonly prescribed medications in neonatal intensive care units (NICUs) and in industrialized countries about 1% of neonates are exposed to antibiotic therapy. Sepsis has often nonspecific signs and symptoms and empiric antimicrobial therapy is promptly initiated in high risk of sepsis or symptomatic infants. However continued use of empiric broad-spectrum antibiotic treatment in the setting of negative cultures especially in preterm infants may not be harmless.

The benefits of antibiotic therapy when indicated are clearly enormous, but the continued use of antibiotics without any microbiological justification is dangerous and only leads to adverse events. The purpose of this review is to highlight the inappropriate use of antibiotics in the NICUs, to exam the impact of antibiotic treatment in preterm infants with negative cultures and to summarize existing knowledge regarding the appropriate choice of antimicrobial agents and optimal duration of therapy in neonates with suspected or culture-proven sepsis in order to prevent serious consequences.

Introduction
Sepsis represent the main cause of neonatal mortality accounting for more than one million neonatal deaths worldwide every year, and antibiotics are the most commonly prescribed medications in the neonatal intensive care units (NICU) [1,2]. Sepsis has often nonspecific signs and implies in serious consequences; as a result, empirical antimicrobial therapy is promptly initiated in symptomatic infants with suspected sepsis after obtaining biological material for culture [1]. However, neonates who do not have infection often receive antimicrobial agents during hospital stay, and inappropriate empirical antibiotic treatment may have serious side effects [3].

Nearly all extremely low birth weight infants (ELBW) infants admitted to a NICU receive an empirical antibiotic treatment in the first postnatal days, in spite of sterile cultures and low incidence of culture-proven bacterial sepsis in this population [1,3,4]. This observation has been confirmed by a study of the National Institute of Child Health and Human Development National Research Network on 6956 very low birth weight (VLBW) infants, showing that 56% of all infants received at least one course of antibiotic treatment, even if proven sepsis was diagnosed in only 21% of all infants [5].

In this review we describe the use of antibiotics in the NICU, focusing on the potential serious adverse effects of inappropriate use; we identify the opportunities for improving antibiotic prescription in the NICU, and we discuss the future directions of antimicrobial therapy.

Epidemiology of bacterial infections in the NICU
Neonatal sepsis can be classified as early-onset (EOS) and late-onset (LOS) sepsis. EOS is most often caused by group B streptococcus (GBS) (43%), followed by Escherichia coli (15.5-29%). Among VLBW infants, the rate of Escherichia coli infection exceeds that of GBS infection (5.1 vs 2.1 per 1000 live births) [3].

LOS is mainly caused by Gram-positive bacteria (GPB) (49%), most often coagulase-negative Staphylococcus (CoNS) (45%). Gram-negative LOS is less common (23%), but is associated with greater mortality in the NICU (19-36%) [6,7].

As showed by various studies, antibiotics such as ampicillin, gentamicin and cefotaxime commonly used for empirical therapy appear to be appropriate. In a recent study, investigators revealed that more than 94% of the EOS isolates were susceptible to penicillin and gentamicin, to amoxicillin and cefotaxime and to cefotaxime alone. The LOS isolates (excluding CONS) had a more than 96% susceptibility to flucloxacillin or amoxicillin and gentamicin, to amoxicillin and cefotaxime, but only 78% to cefotaxime alone. The investigators concluded that cefotaxime should not be included in the empiric regimen of suspected sepsis, because of lower susceptibility levels [7].

Blackburn et al, in a study of neonatal septicemia found that only 1.4% of Gram-negative bacteria (GNB) were resistant to penicillin plus gentamicin, whereas 10.4% of isolates tested against amoxicillin plus cefotaxime were resistant to this association [8].

Most hospital acquired CoNS are resistant to many commonly prescribed antibiotics. In the NICU, enterococci are less frequently isolated than staphylococcal species. Nevertheless,
ampicillin-resistant, and, more recently, vancomycin-resistant enterococci have been described and have become endemic in some NICUs [9].

GNB are often resistant to at least one class of antibiotics usually used, and bacteria that are multi- or extensively-resistant to conventional antibiotics are frequently isolated. Pan-resistant pathogens are rarely isolated in the NICUs, where resistance is most frequently found to piperacillin-tazobactam, ceftazidime, and/or gentamicin [9,10].

Moreover, the emergence of extended-spectrum β-lactamase (ESBL)-producing GNB confers resistance to penicillins and cephalosporins, often coexisting with other antibiotic categories as fluoroquinolones and aminoglycosides [9,11].

**Risks associated with empirical administration of broad-spectrum antibiotics**

The use of broad-spectrum antibiotics is associated with different adverse effects: alteration of gut colonization, emergency of resistant strains, and increasing risk of Candida colonization and subsequent invasive candidiasis [4].

All antibiotics can alter gut colonization of the patient, promoting either antibiotic resistance among normal commensal organisms or the emergence of other pathogens [4,12].

A number of in vitro and in vivo studies have shown that, although short courses of carbapenems and third-generation cephalosporins cover a broad spectrum of bacteria, their prolonged and intensive use selects resistant bacteria. Overuse of third-generation cephalosporins favors the emergence of ESBL-producing strains of GNB in NICUs [10,13].

In order to study the effects of empirical antibiotics on the emergence of resistant pathogens, de Man et al. [14] examined 436 infants admitted to 2 NICUs who were assigned initially to either a narrow-spectrum antibiotic regimen (penicillin or flucloxacillin plus tobramycin) or a broad-spectrum regimen (amoxicillin plus cefotaxime) and exchanged regimens after 6 months. The investigators demonstrated that the relative risk for colonization with strains resistant to empirical therapy per 1000 patients at risk was 18-fold higher in the broad-spectrum regimen group than in the narrow-spectrum regimen group.

Exposure to broad spectrum antibiotics has been also associated with the emergence of invasive candidiasis. In a cohort of 3,702 ELBW infants, previous use of third generation cephalosporins or carbapenems were associated with an increased risk of invasive candidiasis (OR 2.2, 95% CI 1.4-3.3). The incidence of candidiasis between centers varied from 2.4% to 20.2% and correlated with the average number of days of broad spectrum antibiotic use per infant with sterile cultures throughout hospitalization [15].

A multicenter cohort study of 128,914 neonates, revealed that the use of ampicillin/cefotaxime during the first 3 days after birth is associated with an increased risk of death before discharge (OR 1.5, 95% CI 1.4-1.7) compared with the use of ampicillin/gentamicin, even if the authors highlighted that this observation may be limited by selection bias. The authors concluded that, for patients receiving ampicillin, the concurrent use of cefotaxime during the first three days after birth is either a surrogate for an unrecognized factor or is itself associated with an increased risk of death, compared with the concurrent use of gentamicin [1].

**Adverse effects of prolonged courses of empirical antibiotic treatment**

For culture-proven sepsis a full course of antibiotics is indicated. Conversely, concerns remain about the optimal length of antibiotic therapy for clinical, not microbiologically demonstrated sepsis. Recent cohort studies show an association between the duration of empirical antibiotic therapy and mortality, necrotizing enterocolitis (NEC) and LOS.

Cotten et al. [16] conducted a retrospective cohort analysis of 5,693 ELBW infants admitted to 19 tertiary centers. Of 5,693 infants, 4,039 survived >5 days, received initial empirical antibiotic treatment and had sterile initial blood culture at 72 hours of life. In a multivariate analysis adjusted for risk factors, prolonged duration of therapy was associated with increased odds of NEC or death or death alone. Each additional day of antibiotic therapy was associated with a 4% increase in the odds of NEC or death, a 7% increase in the odds of NEC alone and a 16% increase in the odds of death alone.

A retrospective 2:1 control case analysis examined the association between antibiotic exposure and the risk of NEC. When neonates with sepsis were removed from cohort, antibiotic

### Table 1 Choice of antibiotics

| **EOS** | Penicillin + gentamicin  
| - if *Listeria monocytogenes: amoxicillin + gentamicin  
| - if *S. aureus: fluclaxocillin + gentamicin |
| **LOS** | First line: fluclaxocillin + gentamicin  
| Second line:  
| - vancomycin + gentamicin (with caution)  
| - vancomycin + piperacillin/tazobactam (to extend Gram-negative cover) |
| **Meningitis** | First line: cefotaxime with amoxicillin ± gentamicin  
| Second line: meropenem |
| **Gram positive multiresistant bacteria** | Currently: glycopeptide antibiotics are the mainstay of therapy, especially vancomycin; if necessary linezolid, clindamycin, rifampicin and daptomycin could be alternative regimens |
| **Gram negative multiresistant bacteria** | In the future: novel cephalosporins like cefaroline and cefodroprone; novel lipoglycopeptide antibiotics are oritavacin and dalbavancin; telavacin has been approved in the USA in adults |
| | Currently: aminoglycosides and cephalosporins are the antibiotics of choice; carbapenems, colistin, co-trimoxazole, tetracycline- and tetracyclins could only be justified in extreme cases. |
| | In the future: treatment options are extremely limited |


*neonatal INTENSIVE CARE* Vol. 29 No. 3 • Summer 2016 45
duration increased the risk of NEC by approximately 20% per day of exposure (OR = 1.2). Exposure for >10 days resulted in nearly a threefold increase in the risk of developing NEC [17].

Prolonged antibiotic therapy has also been associated with LOS. A retrospective study of 365 infants ≤32 weeks gestational age (GA) and ≤1500 g birth weight (BW), who survived free of sepsis and NEC in the first week of life, found that prolonged antibiotic therapy (≥5 days) initiated on the day of birth was independently associated with LOS alone and the composite outcome of LOS, NEC or death. Each additional day of antibiotics was associated with a significantly increased risk of these outcomes. For infants who received any initial empirical antibiotic exposure, the adjusted attributable risk for LOS, NEC or death was 32% and the number needed to harm was 3 [18].

**Recommendations for a judicious use of antibiotics**

**Choice of the antibiotic agent**

Concerning the newborn infants, there are no randomized controlled trials that can definitely prove the best choice of antibiotics. However, many authors agree that an association of a penicillin or semisynthetic penicillin (ampicillin) together with an aminoglycoside is effective against microorganisms causing EOS, and therefore can be considered the best empirical regimen [10,19,20].

For the treatment of suspected LOS, different authors agree that the best regimen is an antistaphylococcal penicillin (oxacillin, flucloxacillin) together with an aminoglycoside; the choice of vancomycin should be restricted to microbiologically demonstrated cases of methicillin-resistant Staphylococcus aureus (MRSA) or CoNS [19,20].

In a recent review, Sivanandan et al. [21] recommended the same antibiotic combinations for empirical therapy of EOS and LOS in neonates. In case of LOS in an instable neonate and in areas where MRSA is prevalent, vancomycin and a third-generation cephalosporin should be considered. For the treatment of suspected early-onset meningitis the authors recommended a combination of ampicillin and aminoglycoside or ampicillin and cefotaxime, and in case of late-onset meningitis a combination of an antistaphylococcal antibiotic (nafcillin or vancomycin) plus a third-generation cephalosporin with or without aminoglycoside.

Russel et al. [12] for the therapy of meningitis suggest as first line treatment the combination of cefotaxime and amoxicillin with or without gentamicin.

Different authors state that empirical therapy should never be started with a broad spectrum antibiotic such as a third-generation cephalosporin or a carbapenem, and their use should be restricted to particular cases [13,19]. Gray et al. [10] suggest the use of piperacillin-tazobactam in the units where aminoglycoside-resistant GBN are prevalent as an alternative to third-generation cephalosporins.

Russel et al. in a recent review, based on epidemiological data from UK neonatal infection surveillance studies, suggest for EOS and LOS treatment, antibiotic strategies reported in Table 1 [12].

**Duration of the antibiotic course**

Culture-proven neonatal sepsis is treated with full course of appropriate antibiotics; the appropriate duration of the antibiotic course is more difficult to be established in case of suspected (clinical) sepsis with negative cultures. Usually, antibiotics are discontinued as soon as blood cultures are confirmed negative (48–72 hours), and if laboratory results and the evolution of the clinical signs allow to exclude an infection [15,21-24].

In case of abnormal laboratory tests [white blood cell count and C-reactive protein (CRP) at age 6–12 h] in well-appearing neonate with negative blood culture Polin and the Committee on Fetus and Newborn [11] (COFN) suggest to continue empiric antibiotic therapy if mother received antibiotics during labor and delivery in case of infants <37 weeks’ gestation with risk factors for sepsis and infants ≥ 37 weeks’ gestation born from mothers with chorioamnionitis.

The algorithms for duration of empiric therapy when cultures are sterile suggested by COFN generated discussion about the lack of strong supportive evidence to guide decisions to stop antimicrobials at 48 h in certain cases.

Cotten et al. [25] in a recent review highlight that current studies are inadequate to specify appropriate testing a timing of diagnostic tests in all situations in which empirical therapy have been started. The authors offer the following suggestions for the management of term and late preterm neonates on empirical therapy for EOS with negative cultures at 48 postnatal hours: i) continuation of treatment for 7 days if clinical signs of sepsis persist over 24 hours; ii) stop antibiotics at 48 hours in asymptomatic neonates with initial (4 postnatal hours) normal complete blood count (initial laboratory tests drawn by risk factors), and in neonates with transient clinical signs (lasting less than 24 h), and abnormal initial complete blood count, if serial CRP measurements at 24 and 48 hours are low in a well-appearing neonate.

In case of culture-proven sepsis, Sivanandan et al [21] suggest that it is reasonable to treat for 10–14 days with appropriate antimicrobial agents infants with blood culture-proven sepsis without meningitis. However, in selected situations [ie neonates >32 weeks GA and >1500 g BW, who became asymptomatic with 5 days of appropriate therapy], it is reasonable to discontinue antibiotics at 7–10 days if laboratory results are normal and cultures are sterile in a well-appearing child. For neonatal meningitis, the same authors suggest a duration of therapy of 14 to 21 days for GBS, ≥ 21 days for Lysteria monocytogenes, a minimum of 21 days for Gram-negative meningitis and 4 to 6 weeks in cases complicated with intracranial abscesses.

**Therapies for resistant pathogens**

Even though an increase in vancomycin MIC values, within the susceptible range, has been registered among isolates of MRSA, CoNS or S. aureus strains vancomycin-intermediate or vancomycin-resistant have not been isolated from a NICU population so far. Consequently, glycopeptides remain an appropriate treatment for most staphylococcal infections in this setting [9,26]. However in case of unresponsive Gram-positive infections, linezolid has been the most used in neonatology, even if the use of daptomycin have been described in few reports in case of persistent staphylococcal bacteremia in neonates [26].

Several novel antibiotics active against GPB are currently in diverse phases of development and clinical trials are ongoing. In particular, advanced-generation cephalosporins like ceftaroline and ceftobiprole with activity against multidrug-resistant staphylococci have been reported in adults [26,27], as well as
lipoglycopeptides agents with activity against multidrug-resistant gram-positive pathogens like oritavancin and dalbavancin and telavancin. All three agents are promising alternatives for the treatment of complicated skin and soft-tissue infections in adults but there are no data about their pharmacokinetics in neonates [26,28].

For serious antibiotic-resistant GNB infections, carbapenems have become the mainstay of treatment with meropenem being the most widely used and doripenem as a newer carbapenem with greater activity against Pseudomonas aeruginosa [10]. However rapid emergence of resistance to these antibiotics means that the use of agents such as colistin, fosfomycin and tigecycline must be considered. Colistin is largely experienced in the neonatal population, but it must be kept in mind that is not effective against Proteus and Serratia. There is little experience of using fosfomycin in neonates but is worth considering as a final-resort therapy for extensively drug-resistant GNB [10,26]. Tigecycline, active against hard to treat pathogens like many multidrug-resistant GPB e GNB, is inactive against Pseudomonas Aeruginosa [10,29], but due to the possible effects on the bone growth in children, the use in neonates could only be justified in extreme cases (Table 1) [10,26].

**Future strategies**

**Appropriate antibiotic policies**

Antimicrobial stewardship programs (ASP) were introduced in the 1980s, with the aim to reduce unnecessary therapies. Nevertheless, only in 2007, the Infectious Diseases Society of America, together with other professional organizations, published guidelines in order to implement multidisciplinary ASP [30]. However, in spite of positive experiences on adults, data about the consequences of ASPs in neonatal settings are lacking.

Recently, several authors suggested different strategies that might be helpful in a NICU that include implementation of systems for surveillance of bloodstream infections, education of practitioners concerning the development of resistance, use of narrow spectrum empirical antibiotic policy and stop of empirical treatment or documented justification for continuation when blood cultures are negative, use of narrowest spectrum antibiotics for a proven infection, formulary restriction and pre-authorization requirements for selected antimicrobial agents like cephalosporins, meropenem, vancomycin and teicoplanin [11,12].

Patel et al [31] suggest that although specific guidelines for neonates are often lacking, antibiotic stewardship principles like those proposed by the Get Smart for Health Care Campaign of the Centers for Disease Control and Prevention can be applied to the NICU along with the development of an interdisciplinary antimicrobial stewardship team and metrics to measure successful implementation of ASP.

**Development of innovative treatments**

Spellberg et al [32] suggest future strategies to combat antibiotic-resistance like therapies with diminished potential to drive resistance (pe infusion of monoclonal antibodies and white cells that kill microbes or biologic agents that alter bacterial ability to trigger inflammation) and treatments that alter host-microbe interactions like moderation of host inflammation and limitation of microbial growth (pe sequestration of host nutrients, probiotics administration that compete with microbial growth).

**Discovery of new antibiotics**

The discovery of new antibiotics must face a number of challenges that make the development of new antibiotic drugs more difficult compared to other non-antibiotic drugs. These have been well summarized in a recent review by Lewis et al [33].

First, the poor penetration of antibiotics in prokaryotic cells requires the delivery of higher amounts of a compound which, in turn, increases the risk of toxicity and narrows the therapeutic range.

In addition, specifically targeting GNB is even more challenging, as not only the inner membrane restricts the penetration of hydrophilic substances, but also the outer membrane further reduces the number of compounds that may be effective, and the multidrug-resistant pumps extrude any compounds that leak in through the outer membrane.

Even when these pharmacodynamics-related issues are resolved, the development of a new drug needs to face the pharmacokinetics-related issues; indeed, the search for molecules with physicochemical properties to improve the likelihood of bioavailability (eg by applying the Lipinski’s rules) may not match with the need of a compound with physicochemical properties that improve penetration into prokaryotes.

Once discovered, the compound must be tested in clinical trials; however, the identification and recruitment of patients infected with multi-resistant bacteria may be difficult, as most infections are caused by pathogens susceptible to the available compounds.

Finally, there is modest return on investment on antibiotic development compared to other drugs. Indeed, antibiotic therapy is typically short-term, lasting only some days, while therapies with cholesterol-lowering drugs or with anti-hypertensive drugs last for years, or lifelong; and, in any case, resistance to the new antibiotics will eventually develop, limiting their use and the profits that it produces.

Despite all these considerations, most of the potential bacterial targets for antibiotics are still unexploited. It is assumed that there are approximately 200 conserved essential proteins in bacteria, but the current antibiotics only hit few targets or pathways [33]. Future efforts should focus on the discovery of compounds directed against these new targets.

**Conclusions**

Sepsis represents the main cause of neonatal mortality and antibiotics are the most commonly prescribed medications in the NICUs. Wise choice of antimicrobial agents and optimal duration of therapy in neonates with suspected or culture-proven sepsis is crucial in order to limit the use of unnecessary broad spectrum antibiotic therapy, and to provide local solutions to the world-wide race against antimicrobial resistance. While there is an increasing choice of drugs for treating multiresistant GPB, alternatives for GNB will be seriously restricted for the foreseeable future. This makes important the need to promote attitudes that fortify measures for infection-control and to develop new treatments that complement traditional approaches.
References


Neonatal Effect Of Remifentanil In General Anaesthesia For Caesarean Section: A Randomized Trial

Pavlina Noskova,1 Jan Blaha,1 Hana Bakhouche,2 Jana Kubatova,1 Jitka Ulrichova,1 Patricia Marusicova,1 Jan Smisek,3 Antonin Parizek,4 Ondrej Slanar2 and Pavel Michalek1

Abstract

Background: Remifentanil has been suggested for its short duration of action to replace standard opioids for induction of general anaesthesia in caesarean section. While the stabilizing effect of remifentanil on maternal circulation has been confirmed, its effect on postnatal adaptation remains unclear, as currently published studies are not powered sufficiently to detect any clinical effect of remifentanil on the newborn.

Methods: Using a double-blinded randomized design, a total of 151 parturients undergoing caesarean delivery under general anaesthesia were randomized into two groups – 76 patients received a bolus of remifentanil prior to induction, while 75 patients were assigned to the control group. Remifentanil 1 μg/kg was administered 30 seconds before the standard induction of general anaesthesia. The primary outcome measure was an assessment of neonatal adaptation using the Apgar score, while secondary outcomes included the need for respiratory support after delivery and differences in umbilical blood gas analysis (Astrup).

Results: The incidence of lower Apgar scores between 0 and 7 was significantly higher in the remifentanil group at one minute (25% vs 9.3% of newborns, p = 0.017); whilst at five minutes and later no Apgar score differences were observed. There was no difference in the need for moderate (nasal CPAP) or intensive (intubation) respiratory support, but significantly more neonates in the remifentanil group required tactile stimulation for respiratory support, but significantly more neonates in the remifentanil group required tactile stimulation for breathing support (21% vs 7% of newborns, p = 0.017). There was no difference in the parameters from umbilical cord blood gas analysis between the groups.

Conclusion: At a dose of 1 μg/kg, remifentanil prior to induction of general anaesthesia increases the risk of neonatal respiratory depression during first minutes after caesarean delivery but duration of clinical symptoms is short.

Background

Opioids are routinely avoided during induction to general anaesthesia for caesarean section because of the potential for respiratory depression in the neonate [1,2]. On the other hand, insufficient depth of analgesia in parturients until foetal delivery remains a concern for obstetric anaesthesiologists [3,4]. Therefore, the ultra short-acting μ1-receptor agonist remifentanil has been suggested as a replacement for longer acting opioids in parturients undergoing caesarean delivery [5-11]. Remifentanil rapidly crosses the placenta but simultaneously is quickly eliminated from the neonatal circulation by degradation with nonspecific esterases in plasma and/or redistribution [12-14]. With a half-life of 3–10 minutes, remifentanil should be almost entirely eliminated from foetal circulation by the time of delivery [15]. However, in obstetrics, despite promising pharmacokinetics and pharmacodynamics, remifentanil is currently more frequently used as a systemic alternative to epidural labour analgesia rather than for general anaesthesia for caesarean delivery [16].

While the stabilizing effect of remifentanil on maternal circulation has been clearly and consistently described in several studies, including the systematic review and meta-analysis published by Heesen and colleagues [17], the effect on postnatal adaptation remains unclear, as these studies have not been sufficiently powered. We therefore aimed our study primarily as a comparison of postnatal adaptation of neonates after caesarean delivery in parturients receiving remifentanil bolus of 1 μg/kg prior to induction of general anaesthesia with those having standard opioid-free induction.

Methods

Study design

This prospective, randomized, controlled, and double-blinded study was conducted at a tertiary care university hospital with an average of 4,600 births per year, in the period between March 2011 and April 2014. The study was approved by the Ethics Committee of the General University Hospital in Prague (MZ10-UKL, Slanar) and registered at the Clinical Trials Database (ClinicalTrials.gov NCT01550640). Study was conducted in accordance with Helsinki Declaration principles. Signed informed consent was obtained from each participant.
Primary objective of the study was to compare newborn postnatal adaptation in parturients undergoing cesarean delivery under general anaesthesia with a remifentanil bolus 1 μg/kg administered prior to the induction of general anaesthesia with those undergoing standard induction. Secondary outcomes were requirements for postoperative respiratory support of neonates and differences in umbilical cord blood gas analysis.

Study population
Eligible patients were parturients undergoing cesarean delivery under general anaesthesia. Patients were screened and enrolled in the study by an anaesthetist during the pre-anaesthesia visit before cesarean delivery. Inclusion criteria were: age of 18 – 45 years. Exclusion criteria included known allergy to remifentanil, multiple pregnancy, gestational age below the 35th week, estimated weight of foetus below 2500 grams, severe foetal hypoxia, severe maternal hypotension, and other serious foetal or maternal conditions. Discontinuation criterion was difficult foetal delivery defined as uterine incision-to-delivery interval >3 min.

Study interventions
Parturients were randomly assigned to two study groups — remifentanil (RMF) or standard (STD). Treatment allocation was performed using online randomization generator (www.randomization.com). Each patient was allocated before entering the operating room. The randomization was kept blinded for the patient, surgeon, and neonatologist. Patients in the RMF group received a bolus of remifentanil 1 μg/kg 30 seconds prior to induction with thiopentone; while all other preoperative, anaesthetic, obstetric and postoperative procedures, were identical for both groups.

General anaesthesia
Standard departmental protocol for cesarean delivery under general anaesthesia was used with metoclopamide and ranitidine administered orally for aspiration prevention. After preoxygenation, general anaesthesia was induced using i.v. thiopentone 5 mg/kg followed by succinylcholine 1.25 mg/kg, and, until delivery; maintained with sevoflurance at an expired concentration of 0.5-0.7% in a 50% gas mixture of nitrous oxide/oxygen. After ligation of the umbilical cord, sufentanil 0.5 μg/kg and atracurium 0.35 mg/kg were administered for analgesia and muscle relaxation and sevoflurane was increased to 1%.

Obstetric management
Pfannenstiel supra-cervical laparotomy and Geppert uterotomy were used in all cases. Oxytocin 5 IU as a bolus was administered intravenously, diluted in 20 ml of saline after removal of the placenta.

Monitoring and evaluation
Intraoperative monitoring was performed using Datex Ohmeda S/5 TM Compact Anaesthesia Monitor (Datex-Ohmeda Inc., USA) according to general standards for patient monitoring during general anaesthesia. Time 0 was determined as the time of remifentanil administration in the RMF group or time 30 sec prior to thiopentone administration in the STD group. The following parameters were monitored; systolic and diastolic non-invasive blood pressure (NIBP syst; NIBP diast), mean blood pressure (MAP), heart rate (HR), electrocardiography (ECG) with ST segment analysis (lead II), pulse oximetry (SpO2), capnography (EtCO2), % of oxygen and volatile anaesthetic, and ventilation parameters (minute ventilation, tidal volume, respiratory rate and maximal inspiratory pressure). To evaluate the depth of anaesthesia, continuous bispectral index analysis (BIS) was used.

Evaluation of newborn adaptation was performed using Apgar scores at 1, 5 and 10 minutes, simultaneously with arterial and venous umbilical cord blood gas analysis and clinical examination. Clinical assessment was undertaken by an experienced neonatologist and acid/base balance status was evaluated directly in the delivery room with ABL 90 Flex (Radiometer Medical, Denmark) blood gas analyser.

Statistical analysis
The sample size of 150 parturients was calculated to detect an overall twofold difference between the groups in the primary outcome (Apgar scores 0–7) with a two-sided 5% significance level and a power of 80%. For sample size calculation, we used data from long term departmental baseline statistics, where Apgar score of 0–7 was observed in 9.5% of caesarean sections under general anaesthesia. A 36-month inclusion period was anticipated to recruit this number of patients.

Statistical analysis was performed with the STATISTICA 10 software (StatSoft, Czech Republic). All data was tested for normality using Kolmogorov-Smirnov test prior to final analysis. Numerical data from both groups was compared using Student’s t-test or Mann–Whitney Rank Sum Test, as appropriate. For categorical variables the Fisher’s exact test and chi-square test were used. All statistical tests were performed two-tailed and values of P < 0.05 were considered statistically significant.

Results
A total of 151 parturients were included in the study, 76 patients were allocated to the remifentanil group while another 75 were assigned to the standard group. All participants were in physical status class I-II according to the American Society of Anesthesiologists. Demographic characteristics of parturients are expressed in Table 1. Figure 1 represents study flow diagram.

<table>
<thead>
<tr>
<th>Table 1 Characteristics of parturients and newborns</th>
</tr>
</thead>
<tbody>
<tr>
<td>Remifentanil group (n = 76)</td>
</tr>
<tr>
<td>Age (years)</td>
</tr>
<tr>
<td>Weight prior to pregnancy (kg)</td>
</tr>
<tr>
<td>Actual weight (kg)</td>
</tr>
<tr>
<td>Height (cm)</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
</tr>
</tbody>
</table>

Medical concomitant diseases
Hypertension 6 (8%) 6 (8%) 0.981
Asthma 4 (5%) 3 (4%) 0.712
Thyreopathy 3 (4%) 3 (4%) 0.987
Diabetes 3 (4%) 2 (3%) 0.660
Placenta praevia centralis 3 (4%) 3 (4%) 0.987
Other 11 (14%) 13 (17%) 0.796

Newborns
Weight of newborns (g) | 3162.9 ± 467 | 3122.5 ± 618 | 0.334 |
Gestational age (weeks) | 38.6 ± 1.1 | 38.9 ± 1.4 | 0.541 |

Data are presented as mean ± standard deviation or n (%).
BMI = Body Mass Index.
German-Belgian team with the inclusion of 186 patients. A meta-analysis conducted and published in 2013 by a delivery under general anaesthesia. However, to our Figure 1 Assessment, randomization, and follow-up of the study patients.

The most frequent reason for employment of general anaesthesia in this study was refusal of regional anaesthesia by the parturient (67 vs 68 patients). In only 9 (RMF group) and 7 (STD group) cases, respectively, the choice of general anaesthesia was based on medical considerations — placenta previa centralis (6 pts.), thrombocytopenia (3 pts.), psychosis (3 pts.), tokophobia (2 pts.), history of spinal trauma (1 pt.) and hypersensitive tetany (1 pt.).

Table 2 Data related to general anaesthesia

<table>
<thead>
<tr>
<th></th>
<th>Remifentanil group (n = 76)</th>
<th>Standard group (n = 75)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Anaesthesia prior foetal delivery</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thiopentone bolus (mg)</td>
<td>398 ± 64</td>
<td>401 ± 68</td>
<td>0.745</td>
</tr>
<tr>
<td>Sevoflurane (%)</td>
<td>0.57 ± 0.2</td>
<td>0.58 ± 0.3</td>
<td>0.586</td>
</tr>
<tr>
<td>SatO₂ (%)</td>
<td>98.4 ± 1.7</td>
<td>97.9 ± 2.3</td>
<td>0.219</td>
</tr>
<tr>
<td>ETCO₂ (kPa)</td>
<td>4.5 ± 0.5</td>
<td>4.4 ± 0.4</td>
<td>0.529</td>
</tr>
<tr>
<td>Induction-to-delivery interval (min)</td>
<td>4.0 ± 1.4</td>
<td>3.9 ± 1.2</td>
<td>0.884</td>
</tr>
<tr>
<td>Duration of surgery (min)</td>
<td>43 ± 9.2</td>
<td>41 ± 9.4</td>
<td>0.724</td>
</tr>
<tr>
<td>Estimated blood loss (ml)</td>
<td>594 ± 196</td>
<td>576 ± 148</td>
<td>0.648</td>
</tr>
<tr>
<td><strong>BIS (%)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline</td>
<td>95.4 ± 4.3</td>
<td>96.2 ± 4.2</td>
<td>0.360</td>
</tr>
<tr>
<td>Tracheal intubation</td>
<td>52.4 ± 16</td>
<td>52.2 ± 12.9</td>
<td>0.930</td>
</tr>
<tr>
<td>Delivery</td>
<td>57.7 ± 13.7</td>
<td>55.7 ± 12.2</td>
<td>0.401</td>
</tr>
<tr>
<td>At 10 min after induction</td>
<td>58.3 ± 10.5</td>
<td>55.8 ± 12.3</td>
<td>0.231</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation. Sevoflurane = mean end expiratory concentration of sevoflurane from induction to delivery; SatO₂ = mean oxygen saturation from induction to delivery; ETCO₂ = mean end tidal capnography from induction to delivery; BIS = bispectral index analysis. Baseline means time before induction to general anaesthesia.

Table 3 Neonatal outcome

<table>
<thead>
<tr>
<th></th>
<th>Remifentanil group (n = 76)</th>
<th>Standard group (n = 75)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Apgar score</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-minute</td>
<td>8.1 ± 2.0</td>
<td>8.9 ± 1.4</td>
<td>0.005</td>
</tr>
<tr>
<td>5-minute</td>
<td>9.2 ± 1.1</td>
<td>9.6 ± 0.8</td>
<td>0.022</td>
</tr>
<tr>
<td>10-minute</td>
<td>9.8 ± 0.5</td>
<td>9.8 ± 0.4</td>
<td>0.198</td>
</tr>
<tr>
<td><strong>Apgar score 0-7</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-minute</td>
<td>19 (25.0%)</td>
<td>7 (9.3%)</td>
<td>0.017</td>
</tr>
<tr>
<td>5-minute</td>
<td>5 (6.6%)</td>
<td>2 (2.7%)</td>
<td>0.442</td>
</tr>
<tr>
<td>10-minute</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Need for respiratory support</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tactile stimulation</td>
<td>16 (21.1%)</td>
<td>5 (6.7%)</td>
<td>0.017</td>
</tr>
<tr>
<td>CPAP</td>
<td>5 (6.6%)</td>
<td>5 (6.7%)</td>
<td>0.983</td>
</tr>
<tr>
<td>Mechanical ventilation</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
<tr>
<td>Administration of naloxone</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td></td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation or n (%). CPAP = continuous positive airway pressure ventilation.

Anaesthesia and surgical baseline management characteristics including delivery time (induction to delivery interval) are shown in Table 2. No intra- or postoperative major complications were recorded during the study.

**Neonatal outcome**

Table 3 and Figure 2 show the characteristics of neonatal postnatal adaptation – Apgar scores and the need for respiratory support. We noted a higher incidence of low Apgar scores between 0 and 7 in the remifentanil group at the first minute (19 vs 7 newborns, p = 0.017), but after the fifth minute no difference between the groups was observed. No difference between the study groups was found in requirement for moderate or intensive respiratory support following delivery (p = 0.983). Temporary CPAP (continuous positive airway pressure ventilation) was employed in 10 newborns (5 in each group), but none required

Table 4 Umbilical cord blood gas analysis

<table>
<thead>
<tr>
<th></th>
<th>Remifentanil group (n = 76)</th>
<th>Standard group (n = 75)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Arterial</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.3 ± 0.0</td>
<td>7.3 ± 0.0</td>
<td>0.210</td>
</tr>
<tr>
<td>pCO₂ (kPa)</td>
<td>6.7 ± 0.7</td>
<td>6.6 ± 0.7</td>
<td>0.450</td>
</tr>
<tr>
<td>HCO₃⁻-act (mmol/l)</td>
<td>25.0 ± 1.9</td>
<td>24.9 ± 1.9</td>
<td>0.786</td>
</tr>
<tr>
<td>HCO₃⁻-std (mmol/l)</td>
<td>22.2 ± 1.9</td>
<td>22.0 ± 1.3</td>
<td>0.567</td>
</tr>
<tr>
<td>BE (mmol/l)</td>
<td>−1.4 ± 1.7</td>
<td>−1.2 ± 1.7</td>
<td>0.645</td>
</tr>
<tr>
<td>pO₂ (kPa)</td>
<td>2.8 ± 0.6</td>
<td>2.6 ± 0.6</td>
<td>0.189</td>
</tr>
<tr>
<td>satO₂ (%)</td>
<td>41.9 ± 14.6</td>
<td>38.0 ± 13.6</td>
<td>0.137</td>
</tr>
<tr>
<td><strong>Venous</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>7.4 ± 0.0</td>
<td>7.3 ± 0.0</td>
<td>0.203</td>
</tr>
<tr>
<td>pCO₂ (kPa)</td>
<td>5.8 ± 0.5</td>
<td>5.8 ± 0.6</td>
<td>0.721</td>
</tr>
<tr>
<td>HCO₃⁻-act (mmol/l)</td>
<td>23.5 ± 1.6</td>
<td>23.4 ± 1.9</td>
<td>0.848</td>
</tr>
<tr>
<td>HCO₃⁻-std (mmol/l)</td>
<td>22.4 ± 1.1</td>
<td>22.2 ± 1.4</td>
<td>0.421</td>
</tr>
<tr>
<td>BE (mmol/l)</td>
<td>−1.7 ± 1.7</td>
<td>−1.8 ± 1.7</td>
<td>0.801</td>
</tr>
<tr>
<td>pO₂ (kPa)</td>
<td>4.6 ± 0.8</td>
<td>4.3 ± 1.1</td>
<td>0.157</td>
</tr>
<tr>
<td>satO₂ (%)</td>
<td>72.6 ± 10.4</td>
<td>68.3 ± 14.4</td>
<td>0.069</td>
</tr>
</tbody>
</table>

Data are presented as mean ± standard deviation.

Figure 1 Assessment, randomization, and follow-up of the study patients.
intubation or admission to a neonatal intensive care unit. There was however, a significant difference in the need for mild breathing support using tactile stimulation during the first 5 minutes (16 vs 5 newborns, \( p = 0.017 \)) (Table 3). No newborn required administration of a \( \mu \)-opioid receptor antagonist.

Table 4 shows umbilical cord arterial and venous blood gas analysis. No difference was observed for any parameter including number of pH values <7.2; such a value was recorded only once (7.18, in the remifentanil group).

**Maternal haemodynamics**

The study groups were equal in basal haemodynamic parameters (blood pressure and heart rate at time 0), but they varied significantly at the time of intubation (both blood pressure and heart rate) and delivery (heart rate). The basal haemodynamic profiles are shown in Table 5.

**Depth of anaesthesia**

No difference was found between the groups after induction of general anaesthesia in depth of anaesthesia (BIS), ST-analysis, or respiratory-ventilation parameters (SatO\textsubscript{2}, EtCO\textsubscript{2}). The profiles of BIS values are shown in Table 2.

**Discussion**

Our study is not the first one to evaluate the effect of remifentanil in parturients undergoing caesarean delivery under general anaesthesia. However, to our knowledge, it is the only one adequately powered to assess the effect on the incidence of respiratory depression during postnatal adaptation of newborns. Moreover, the other important aspect of our study is its sample size. With 151 patients participating in the study and 76 in the remifentanil group, this is the largest remifentanil assessment in obstetric patients undergoing caesarean delivery. The size of our homogenous study group should be highlighted especially in comparison to the meta-analysis conducted and published in 2013 by a German-Belgian team with the inclusion of 186 patients from 5 randomized clinical trials [17].

While published studies agree on the positive effect of remifentanil on reducing adverse haemodynamic response to intubation and surgery during caesarean delivery, they vary in terms of its effect on neonatal adaptation. Yoo [18] and Ngan Kee [15] used an identical bolus of remifentanil — 1 \( \mu \)g/kg. They highlighted, similarly to our study, a risk of transient, neonatal respiratory depression. In contrast, Bouattour and colleagues did not demonstrate any attenuation of neonatal adaptation after administration of 0.5 \( \mu \)g/kg of remifentanil [19]. More worrying, 14.3% of newborns in another study had to be intubated for respiratory support, following a pre-induction dose of remifentanil 0.5 \( \mu \)g/kg [20]. The determination of a remifentanil “safe dose”, not causing adverse effect on neonate, was not even unravelled by the aforementioned meta-analysis performed by Heesen et al. [17].

In our study, we observed a significantly higher incidence of moderate to severe aggravation of neonatal adaptation (Apgar scores 0–7) after remifentanil administration (\( p = 0.017 \)). However, in all cases, neonatal respiratory depression lasted only for several minutes because lower Apgar scores were observed at the 1st minute only. The Apgar scores were similar at 5 minutes, which is a more crucial time for subsequent neonatal care and/or eventual transfer to neonatal intensive care unit. In total, 28% of neonates in the remifentanil group required some form of respiratory support after delivery, however they mostly responded only to tactile stimulation.

The observed incidence of short-time lasting, deteriorated postpartum neonatal adaptation was quite high in the remifentanil group, although its clinical significance and severity are not clear. A hypothetical explanation of different results in published studies could be the existence of genetic polymorphism of the placenta transporting system glycoprotein P (multidrug resistance gene 1, MDR1) and polymorphism of \( \mu \)-receptors and then divergent transfer of remifentanil into the foetal circulation [21,22]. Another reason for relatively higher incidence of respiratory depression in our study may also be shorter time of foetal delivery (4.0 min induction-to-delivery time) compared to some other centres [20,23,24]. We may hypothesize that remifentanil with its half-life of 3–10 minutes was not completely eliminated at the time of delivery. This could explain why Yoo et al. [24] found no significantly higher depression rate, even with a dose of 1.25 \( \mu \)g/kg. It should be noted that they reported interval to delivery approximately 10 minutes, which is potentially longer than expected effect of remifentanil.

It should be also highlighted that postnatal adaptation of the newborn is affected by previous intrauterine foetal condition, concurrent administration of thiopentone and volatile anaesthetics, as well as by induction-to-delivery interval.
and technique of caesarean section. Therefore we excluded parturients with expected alteration of neonatal respiratory function (immaturity of foetus or in utero pathologies). In order to decrease bias of the study, we also excluded females with multiple pregnancy (risk of low birth weight and prematurity) and newborns following difficult delivery with uterine incision-to-delivery interval more than 3 min [25-27]. Nevertheless, we observed 14% incidence of moderate respiratory depression even in the standard group, with 5 newborns requiring the use of CPAP. Specific reasons for this depression remain unclear even after detailed analysis of individual cases (with no noted significant differences in delivery interval, gestational age or weight, blood gas analysis results or maternal demographic, respiratory or haemodynamic parameters).

In contrast to other studies, we did not find any difference in the umbilical cord blood gas analysis parameters, including Base Excess reported in Heesen’s meta-analysis [17]. Acid/base balance parameters in umbilical cord blood correspond with the status of foetal oxygenation at the time of delivery. We detected only new born in the remifentanil group presenting with pH <7.2, which may be associated with increased neonatal morbidity [28]. Therefore, our assessment of remifentanil effect on neonatal adaptation should not have been affected by concurrent foetal intrauterine hypoxia.

We are aware of limitations of our study. Although the adaptation of each newborn was evaluated by experienced neonatologist, requirements to stimulate their breathing by tactile stimulation might still be biased by inter-individual differences. Another limitation may be exclusion of deliveries indicated for acute foetal hypoxia. General anaesthesia is most commonly administered in such cases, where suppression of stress response to tracheal intubation and surgical stimuli would be theoretically desirable.

Forming a consensus with other published trials, we also recorded the positive effect of remifentanil on the suppression of cardiovascular stress response to tracheal intubation and surgery. A dose of remifentanil 1 μg/kg given 30 seconds prior to induction of general anaesthesia effectively reduced a rise in both blood pressure and heart rate until delivery of foetus. Whereas the haemodynamic monitoring wasn’t the main aim of this study, it was not blinded for anaesthesiologist. Therefore its interpretation might be burdened by a potential bias, albeit most likely only an insignificant. The haemodynamic profile herein is given primarily within an overall description of intraoperative course of our study.

Unlike its stabilizing effect on the cardiovascular system, the dose of remifentanil 1 μg/kg did not affect the depth of anaesthesia. BIS values were below 60 in both groups throughout the study. This value has been accepted as a threshold which should decrease the incidence of awareness [29,30]. Similar results have been reported in other studies [18]. It is assumed that the majority of hypnotic effect during induction is achieved by the initial dose of thiopentone potentiated by anaesthetic gases, while remifentanil in this dose has only small effect on depth of anaesthesia [31].

**Conclusion**

We demonstrated that a pre-induction dose of remifentanil 1 μg/kg is associated with a relatively high risk of neonatal respiratory depression. However, this attenuation was present only in the first five minutes after delivery and its clinical significance seems to be rather mild. Remifentanil is a suitable choice of co-induction agent in parturients who could be prone to excessive hypertension and tachycardia during induction to anaesthesia. In these cases, careful postnatal care must be applied if respiratory depression is observed.

**References**


Partnership for a Smooth ENFit™ Transition

NeoConnect Products for the NICU
- Complies with ASPEN recommendations for effective cleaning options of the ENFit feeding tube hub to protect against bacteria colonization
- Keeps features from the legacy line, such as self-righting tip caps and off-centered tip syringes
- Available in orange and purple
- Cleaning Tool, Low Dose syringes, and the DoseMate Oral Administration Tip

NeoConnect Products for the Pharmacy
- Complies with ISMP Recommendations and GEDSA Position Statements
- Eliminates the need for transition sets or temporary adapters, which can create unrecognized priming volume and dead space
- Low dose syringes, bottle caps, click-to-close tip caps, straws and the DoseMate to meet the needs of all patient populations in all clinical settings

NeoMed is committed to the highest level of service to our customers during the transition to ENFit. The NeoMed Loyalty Program helps align your product needs and supply chain integrity with Go Live dates, while supporting hospital staff training and process protocol review.
The BEST Nutritional Warmer just got BETTER!

- New Enteral Warming Feature
- Superior Infectious Control
- 30% Reduced Footprint
- Large Color HD Display

Penguin® Enteral Warmer

- Works with ALL BRANDS of Enteral Pumps & Sets
- FDA 510 (K) Certified

Penguin® Refrigerator

- Drawer Design
  Quick cooling recovery
- Whisper™ Quiet Technology
  Ambient noise level of less than "39 decibels"
- Micro-Size / Space Saving
  Mounts under a standard/ADA counter

Penguin® Nutritional Warmer

- Built-in Refrigerator
- Doubles as a Preparation Cart
- Color Choices to match décor with solid surface options
- Built-in Electrical Outlets for patient convenience
- Family Locker
  Storage of personal belongings

Custom Nightstand

- Built-in Refrigerator
- Doubles as a Preparation Cart
- Color Choices to match décor with solid surface options
- Built-in Electrical Outlets for patient convenience
- Family Locker
  Storage of personal belongings

Creche Innovations
17745 Metcalf, One Penguin Plaza, Stilwell, KS 66085
(913) 948.6290 info@crecheinnovations.com www.CrecheInnovations.com